{"questions": [{"id": "6402c910201352f04a00000c", "type": "yesno", "body": "Can losartan reduce brain atrophy in Alzheimer's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20838622", "http://www.ncbi.nlm.nih.gov/pubmed/34687634", "http://www.ncbi.nlm.nih.gov/pubmed/29226862", "http://www.ncbi.nlm.nih.gov/pubmed/31135048", "http://www.ncbi.nlm.nih.gov/pubmed/20620665"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34687634", "text": "TION\n12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinicall", "offsetInBeginSection": 2590, "offsetInEndSection": 2740, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29226862", "text": "ing visits.\n\n\nCONCLUSION\nThis study will identify whether losartan is efficacious in the treatment of AD and whether definitive Phase III trials are w", "offsetInBeginSection": 1846, "offsetInEndSection": 1996, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20620665", "text": "ging initiative (ADNI) dataset to assess if adjusting for baseline characteristics can reduce sample sizes. Controls (n = 199), patients with mild cog", "offsetInBeginSection": 142, "offsetInEndSection": 292, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31135048", "text": "Medial temporal sparing in non-amnestic Alzheimer's disease may thus be due in part to later onset of medial temporal degeneration than in amnestic patients", "offsetInBeginSection": 2293, "offsetInEndSection": 2449, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20838622", "text": " mild cognitive impairment can be slowed by treatment with homocysteine-lowering B vitamins. Sixteen percent of those over 70 y old have mild cognitiv", "offsetInBeginSection": 1933, "offsetInEndSection": 2083, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20620665", "text": "tment trials in AD should consider the effects of normal aging; adjusting for baseline characteristics can significantly reduce required sample sizes.", "offsetInBeginSection": 1248, "offsetInEndSection": 1398, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640f857d201352f04a00002b", "type": "factoid", "body": "What is CHARMS with respect to medical review of predictive modeling?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33364802", "http://www.ncbi.nlm.nih.gov/pubmed/36149932", "http://www.ncbi.nlm.nih.gov/pubmed/35493941", "http://www.ncbi.nlm.nih.gov/pubmed/33594834", "http://www.ncbi.nlm.nih.gov/pubmed/32583899", "http://www.ncbi.nlm.nih.gov/pubmed/31762119", "http://www.ncbi.nlm.nih.gov/pubmed/31090660", "http://www.ncbi.nlm.nih.gov/pubmed/33492724", "http://www.ncbi.nlm.nih.gov/pubmed/31439598"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/31762119", "text": "ist for critical Appraisal and data extraction for systematic Reviews of prediction Modeling Studies [CHARMS] and Prediction model Risk Of Bias ASsess", "offsetInBeginSection": 116, "offsetInEndSection": 266, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31439598", "text": "st for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) checklist.\n\n\nPRIMARY AND SECONDARY OUTCO", "offsetInBeginSection": 690, "offsetInEndSection": 840, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33492724", "text": " the CHARMS recommendations (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies), extracting the informatio", "offsetInBeginSection": 405, "offsetInEndSection": 555, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32583899", "text": "The CHARMS (critical appraisal and data extraction for systematic reviews of prediction modelling studies) checklist was created to provide methodolog", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660", "text": "ist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) checklist. In total 89,959 citations wer", "offsetInBeginSection": 389, "offsetInEndSection": 539, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35493941", "text": "racted the data. We used the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS) checklist for the r", "offsetInBeginSection": 864, "offsetInEndSection": 1014, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33594834", "text": "tems from the CHEERS checklist for economic evaluations and the CHARMS checklist for evaluation of prediction studies.\n\n\nRESULTS\nFrom 38 selected stud", "offsetInBeginSection": 960, "offsetInEndSection": 1110, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33364802", "text": "tical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) and the prediction model risk of bias assessment to", "offsetInBeginSection": 517, "offsetInEndSection": 667, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36149932", "text": " and undertook data extraction following recommendations of the CHARMS checklist, while quality assessment was performed using the PROBAST tool. A tot", "offsetInBeginSection": 1027, "offsetInEndSection": 1177, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410eb95201352f04a00002e", "type": "list", "body": "Which splicing factors have been associated with alternative splicing in PLN R14del hearts?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36375644", "http://www.ncbi.nlm.nih.gov/pubmed/35191471"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/36375644", "text": "formatical analysis pointed to the tissue-specific splicing factors Srrm4 and Nova1 as likely upstream regulators of the observed splicing changes in ", "offsetInBeginSection": 1271, "offsetInEndSection": 1421, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35191471", "text": "raction or cardiac output. Challenge of ex vivo hearts with isoproterenol and rapid pacing unmasked higher propensity for sustained ventricular tachyc", "offsetInBeginSection": 914, "offsetInEndSection": 1064, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64162fb0690f196b5100001a", "type": "list", "body": "What are the most common mutation types in Duchenne muscular Dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23620649", "http://www.ncbi.nlm.nih.gov/pubmed/33039804", "http://www.ncbi.nlm.nih.gov/pubmed/33741226"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33741226", "text": "ssociated to DMD gene mutations include now low IQ scores, epilepsy, autism, and attention deficit disorder. These have been observed with higher freq", "offsetInBeginSection": 135, "offsetInEndSection": 285, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23620649", "text": "Xlinked dystrophin gene (about 65% deletions, about 7% duplications, about 26% point mutations and about 2% unknown mutations). The clinically milder ", "offsetInBeginSection": 115, "offsetInEndSection": 265, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33039804", "text": "in children and is clinically characterized by progressive muscle degeneration and severe cardiomyopathy. In this study, renal epithelial cells were o", "offsetInBeginSection": 134, "offsetInEndSection": 284, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eef3ebf36125a42600000a", "type": "factoid", "body": "What is the target of Litifilimab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26670814", "http://www.ncbi.nlm.nih.gov/pubmed/36069871", "http://www.ncbi.nlm.nih.gov/pubmed/35939578", "http://www.ncbi.nlm.nih.gov/pubmed/1477416"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/36069871", "text": "4, 8, 12, 16, and 20, with the primary end point of evaluating cutaneous lupus activity. The trial design was subsequently modified; adults with SLE, ", "offsetInBeginSection": 686, "offsetInEndSection": 836, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939578", "text": "ne the effect and safety of litifilimab for the treatment of cutaneous lupus erythematosus. (Funded by Biogen; LILAC ClinicalTrials.gov number, NCT028", "offsetInBeginSection": 2523, "offsetInEndSection": 2673, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1477416", "text": "ctivate already activated T cells remains unclear. Assuming that the T lymphocyte is the target site for CS, local therapy reaches only a small fracti", "offsetInBeginSection": 997, "offsetInEndSection": 1147, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26670814", "text": "her targeted temperature (36\u00a0\u00b0C). Thus, recent data suggest that avoiding hyperpyrexia, rather than cooling \"per se,\" may be considered the main thera", "offsetInBeginSection": 487, "offsetInEndSection": 637, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36069871", "text": "uired to determine the safety and efficacy of litifilimab for the treatment of SLE. (Funded by Biogen; LILAC ClinicalTrials.gov number, NCT02847598.).", "offsetInBeginSection": 2468, "offsetInEndSection": 2618, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64136fbf201352f04a00003d", "type": "factoid", "body": "What is AUROC in context of predictive modeling?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34154565", "http://www.ncbi.nlm.nih.gov/pubmed/32930711", "http://www.ncbi.nlm.nih.gov/pubmed/34865209", "http://www.ncbi.nlm.nih.gov/pubmed/35879562", "http://www.ncbi.nlm.nih.gov/pubmed/33203588", "http://www.ncbi.nlm.nih.gov/pubmed/31304302", "http://www.ncbi.nlm.nih.gov/pubmed/31093546", "http://www.ncbi.nlm.nih.gov/pubmed/36329470", "http://www.ncbi.nlm.nih.gov/pubmed/25958031", "http://www.ncbi.nlm.nih.gov/pubmed/35505048"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35879562", "text": "cognitive impairment was evaluated using area under the receiver operating characteristic curve (AUROC), and multivariate logistic regression was appl", "offsetInBeginSection": 360, "offsetInEndSection": 510, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32930711", "text": "gression, using UMLS delivered the optimal area under the receiver operating characteristics (AUROC) results in both dengue hemorrhagic fever (81.15%)", "offsetInBeginSection": 1005, "offsetInEndSection": 1155, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25958031", "text": "ndings). Sensitivity, specificity, predictive values and area under receiving operating curves (AUROC) of RBUS for VCUG abnormalities were determined.", "offsetInBeginSection": 1325, "offsetInEndSection": 1475, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34865209", "text": "s). Model performance was assessed using area under the receiver operator characteristic curve (AUROC). Pre-N8-GP prophylaxis models learned from data", "offsetInBeginSection": 598, "offsetInEndSection": 748, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34154565", "text": "iagnostic threshold were evaluated using area under the receiver operating characteristic curve (AUROC). Stratification analysis by age and MP-IgM tit", "offsetInBeginSection": 536, "offsetInEndSection": 686, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35505048", "text": " learning algorithms was assessed by the area under the receiver operating characteristic curve (AUROC). The conventional scoring models had various p", "offsetInBeginSection": 543, "offsetInEndSection": 693, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33203588", "text": "sing PubMed, MEDLINE, and Scopus databases. Papers with area under the receiver operating curve (AUROC) scores reported were included in the analysis.", "offsetInBeginSection": 471, "offsetInEndSection": 621, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36329470", "text": "onstruct the prediction model. Finally, the area under the receiver operating characteristic (AUROC) curve was used to compare the model performance.\n", "offsetInBeginSection": 837, "offsetInEndSection": 987, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31304302", "text": "cy for tasks such as predicting: in-hospital mortality (area under the receiver operator curve [AUROC] across sites 0.93-0.94), 30-day unplanned readm", "offsetInBeginSection": 1029, "offsetInEndSection": 1179, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31093546", "text": "ognostic tests. Rather, researchers use the area under the receiver operating characteristic (AUROC) as the key metric to gauge and report predictive ", "offsetInBeginSection": 112, "offsetInEndSection": 262, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63fa13da201352f04a000001", "type": "yesno", "body": "Is PRP-40 regulation of microexons a conserved phenomenon?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34348142", "http://www.ncbi.nlm.nih.gov/pubmed/33621242"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33621242", "text": " are extremely small exons (3-27 nucleotides long) that are highly evolutionarily conserved and play critical roles in promoting neuronal differentiat", "offsetInBeginSection": 133, "offsetInEndSection": 283, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34348142", "text": "d dysregulation of microexons but not conventionally sized exons. PRP-40 regulation of neuronal microexons is therefore a widely conserved phenomenon.", "offsetInBeginSection": 945, "offsetInEndSection": 1095, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64178e15690f196b51000020", "type": "yesno", "body": "Is casimersen effective for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19179609", "http://www.ncbi.nlm.nih.gov/pubmed/30796500", "http://www.ncbi.nlm.nih.gov/pubmed/12843632", "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "http://www.ncbi.nlm.nih.gov/pubmed/19517771", "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "http://www.ncbi.nlm.nih.gov/pubmed/34105177", "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "http://www.ncbi.nlm.nih.gov/pubmed/34553378"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19517771", "text": "ing gene transfer strategies have been conducted, but no effective treatment has been established. Two plausible ways have been proposed. One is the i", "offsetInBeginSection": 294, "offsetInEndSection": 444, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34553378", "text": "uscular dystrophy (DMD) is a degenerative muscle disease with no effective drug treatment. This study investigated the positive effects of fenofibrate", "offsetInBeginSection": 33, "offsetInEndSection": 183, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "text": "r dystrophy is a lethal neuromuscular disease that currently has no effective therapy. Transgenic overexpression of the alpha7 integrin in mdx/utrn(-/", "offsetInBeginSection": 16, "offsetInEndSection": 166, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "text": "se of mortality among Duchenne muscular dystrophy patients and lacks effective therapies. Phosphodiesterase type 5 is implicated in dystrophic patholo", "offsetInBeginSection": 42, "offsetInEndSection": 192, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "text": "es, most commonly as limb-girdle muscular dystrophy 2I. There is no effective therapy available. Glucocorticoid steroids have become the standard trea", "offsetInBeginSection": 137, "offsetInEndSection": 287, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12843632", "text": "dystrophin, a 427-kDa cytoskeletal protein, but the effective therapeutic drug is presently unavailable. We previously reported that a trypsin-like pr", "offsetInBeginSection": 73, "offsetInEndSection": 223, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34105177", "text": "etic parameters were similar at weeks 7 and 60.\n\n\nDISCUSSION\nCasimersen was well tolerated in participants with DMD amenable to exon 45 skipping. Most", "offsetInBeginSection": 1417, "offsetInEndSection": 1567, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30796500", "text": "ith Duchenne muscular dystrophy experienced severe acute heart failure triggered by pneumonia. Levosimendan was effective in improving heart function.", "offsetInBeginSection": 264, "offsetInEndSection": 414, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34105177", "text": "o exon 45 skipping. Our primary study objective was to evaluate safety and tolerability of casimersen; the secondary objective was to characterize the", "offsetInBeginSection": 321, "offsetInEndSection": 471, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "text": "ive degeneration of skeletal and cardiac muscles. Currently, there is no effective therapy for this disorder. However, the technology of cell reprogra", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f02ceaf36125a426000015", "type": "summary", "body": "Which are the targets of Tirzepatide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32730231", "http://www.ncbi.nlm.nih.gov/pubmed/35674880", "http://www.ncbi.nlm.nih.gov/pubmed/35210595", "http://www.ncbi.nlm.nih.gov/pubmed/35468321", "http://www.ncbi.nlm.nih.gov/pubmed/34984793", "http://www.ncbi.nlm.nih.gov/pubmed/35767712", "http://www.ncbi.nlm.nih.gov/pubmed/35830001", "http://www.ncbi.nlm.nih.gov/pubmed/36050763", "http://www.ncbi.nlm.nih.gov/pubmed/36004653"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35210595", "text": "ptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity. Its association with cardiovascular outcomes requires ev", "offsetInBeginSection": 56, "offsetInEndSection": 206, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34984793", "text": "RA tirzepatide resulted in increasing numbers of people reaching HbA1c and body weight targets, with up to 62% attaining normoglycaemia with 15-mg tir", "offsetInBeginSection": 1479, "offsetInEndSection": 1629, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35767712", "text": "M. This first-in-class agent serves as a coagonist for both the GLP-1 and GIP receptors. In this review, we report on the pharmacologic mechanism of G", "offsetInBeginSection": 897, "offsetInEndSection": 1047, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35468321", "text": "r baseline. The secondary outcomes were to compare tirzepatide (5 mg, 10 mg, and 15 mg) versus insulin degludec for the proportion and duration of tim", "offsetInBeginSection": 1783, "offsetInEndSection": 1933, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35830001", "text": "cise. Tirzepatide is in phase III development for heart failure, obesity and cardiovascular disorders in T2DM, and in phase II development for non-alc", "offsetInBeginSection": 819, "offsetInEndSection": 969, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35674880", "text": "nder development for long-term weight management, heart failure with preserved ejection fraction, and nonalcoholic steatohepatitis. This study evaluat", "offsetInBeginSection": 221, "offsetInEndSection": 371, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36050763", "text": "incretin agonist, over GLP-1RA will spark renewed interest in the therapeutic potential of GIP in type 2 diabetes, obesity and related co-morbidities.", "offsetInBeginSection": 2516, "offsetInEndSection": 2666, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36004653", "text": "cular dual agonist of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, which is developed as onc", "offsetInBeginSection": 24, "offsetInEndSection": 174, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35468321", "text": "onal evidence to the effect of tirzepatide and potential for achieving glycaemic targets without increase of hypoglycaemic risk compared with a basal ", "offsetInBeginSection": 3278, "offsetInEndSection": 3428, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32730231", "text": "nder development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis. Early phase trials in T2DM indicate ", "offsetInBeginSection": 66, "offsetInEndSection": 216, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640e2616201352f04a00002a", "type": "yesno", "body": "Is medical hydrology the same as Spa therapy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12110784"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/12110784", "text": "venous disorders in Europe, but whether the practice is associated with health or social benefits remains controversial.\n\n\nMETHODS\nThe present work is", "offsetInBeginSection": 159, "offsetInEndSection": 309, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410fa66201352f04a000034", "type": "summary", "body": "How does CYP1A2 relate to coffee consumption and apetite?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18157525", "http://www.ncbi.nlm.nih.gov/pubmed/18398030"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18157525", "text": "erbs than in Swedes (P=0.0003).\n\n\nCONCLUSIONS\nHabitual heavy coffee consumption increases CYP1A2 activity. Polycyclic aromatic hydrocarbons formed dur", "offsetInBeginSection": 1326, "offsetInEndSection": 1476, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18398030", "text": "CYP1A2 plays a key role in the metabolism of both estrogen and coffee. Women with higher coffee intake and the CYP1A2*1F A/A genotype have a ratio of ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18157525", "text": "consumption of at least three cups of coffee significantly increased CYP1A2 enzyme activity in both Serbs (P=0.0002) and Swedes (P<0.0001). Among non-", "offsetInBeginSection": 602, "offsetInEndSection": 752, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64178e73690f196b51000023", "type": "yesno", "body": "Is eteplirsen effective for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32691988", "http://www.ncbi.nlm.nih.gov/pubmed/34120909", "http://www.ncbi.nlm.nih.gov/pubmed/30526286", "http://www.ncbi.nlm.nih.gov/pubmed/30801483", "http://www.ncbi.nlm.nih.gov/pubmed/30195785", "http://www.ncbi.nlm.nih.gov/pubmed/26573217", "http://www.ncbi.nlm.nih.gov/pubmed/32483212"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/32691988", "text": "nne muscular dystrophy (DMD), reviewing studies that evaluate the respiratory effect of eteplirsen, the cardiopulmonary effects of ataluren, and a stu", "offsetInBeginSection": 232, "offsetInEndSection": 382, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26573217", "text": "s remained relatively stable in eteplirsen-treated patients. Eteplirsen was well tolerated. Analysis of HC confirmed the previously observed change in", "offsetInBeginSection": 1183, "offsetInEndSection": 1333, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30801483", "text": "We review the development of exon 51 skipping therapy with eteplirsen for Duchenne muscular dystrophy, including the recent report of long-term, susta", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34120909", "text": "BackgroundEteplirsen received accelerated FDA approval for treatment of Duchenne muscular dystrophy (DMD) with mutations amenable to exon 51 skipping,", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212", "text": "earlier this year. Although promising, the efficacy of eteplirsen and AON sequence employed remain controversial. In addition, exon skipping faces cha", "offsetInBeginSection": 551, "offsetInEndSection": 701, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30195785", "text": "herapeutics for Duchenne muscular dystrophy patients. However, the limited efficacy of eteplirsen underscores the importance to improve systemic deliv", "offsetInBeginSection": 90, "offsetInEndSection": 240, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30526286", "text": "Eteplirsen was approved for the treatment of eligible patients with Duchenne muscular dystrophy (DMD) in September 2016 in one of the most, if not the", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212", "text": " promising, the efficacy of eteplirsen and AON sequence employed remain controversial. In addition, exon skipping faces challenges including the appli", "offsetInBeginSection": 578, "offsetInEndSection": 728, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34120909", "text": "s to the growing body of evidence for eteplirsen, confirming a positive treatment effect, favorable safety profile, and slowing of disease progression", "offsetInBeginSection": 1692, "offsetInEndSection": 1842, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26573217", "text": "OBJECTIVE\nTo continue evaluation of the long-term efficacy and safety of eteplirsen, a phosphorodiamidate morpholino oligomer designed to skip DMD exo", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f03939f36125a42600001b", "type": "summary", "body": "What is the use of darolutamide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32905676", "http://www.ncbi.nlm.nih.gov/pubmed/36087070", "http://www.ncbi.nlm.nih.gov/pubmed/32436836", "http://www.ncbi.nlm.nih.gov/pubmed/34797506", "http://www.ncbi.nlm.nih.gov/pubmed/33135506", "http://www.ncbi.nlm.nih.gov/pubmed/35179323", "http://www.ncbi.nlm.nih.gov/pubmed/34866168", "http://www.ncbi.nlm.nih.gov/pubmed/33226524", "http://www.ncbi.nlm.nih.gov/pubmed/32073798"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33135506", "text": "alutamide, enzalutamide, and most recently, darolutamide (novel androgen receptor antagonists) have been approved for nonmetastatic castration-resista", "offsetInBeginSection": 183, "offsetInEndSection": 333, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32436836", "text": "D\nDarolutamide is recently approved for the treatment of non-metastatic castrate resistance prostate cancer. Hitherto, no stereoselective pharmacokine", "offsetInBeginSection": 9, "offsetInEndSection": 159, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33226524", "text": "amide 600\u00a0mg twice daily or matched placebo while continuing androgen deprivation therapy. The primary endpoint was MFS.\n\n\nRESULTS\nIn Japan, 95 patien", "offsetInBeginSection": 526, "offsetInEndSection": 676, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34866168", "text": "ndrogen receptor inhibitor approved for the treatment of nonmetastatic castration-resistant prostate cancer at a dosage of 600 mg orally twice daily.\n", "offsetInBeginSection": 48, "offsetInEndSection": 198, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36087070", "text": "OBJECTIVE\nTo assess, the effect of darolutamide (a structurally distinct androgen receptor inhibitor) on urinary and bowel symptoms, using data from t", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32905676", "text": "eceptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phas", "offsetInBeginSection": 61, "offsetInEndSection": 211, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34797506", "text": "INTRODUCTION\nApalutamide and darolutamide are next-generation androgen receptor inhibitors that have demonstrated superior efficacy compared to placeb", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32073798", "text": "al show that the androgen receptor antagonist darolutamide improves metastasis-free survival in men with non-metastatic, castration-resistant prostate", "offsetInBeginSection": 55, "offsetInEndSection": 205, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34797506", "text": "shed data from the ARAMIS study (darolutamide\u00a0+\u00a0ADT) for clinically relevant baseline measures. Hazard ratios (HR) and 95% credible intervals (CrI) we", "offsetInBeginSection": 620, "offsetInEndSection": 770, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35179323", "text": "BACKGROUND\nDarolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetast", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64136664201352f04a00003b", "type": "list", "body": "What are the main clinical features of small-fiber neuropathy (SFN)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33802768", "http://www.ncbi.nlm.nih.gov/pubmed/23982054", "http://www.ncbi.nlm.nih.gov/pubmed/34075618", "http://www.ncbi.nlm.nih.gov/pubmed/22570215", "http://www.ncbi.nlm.nih.gov/pubmed/30968230", "http://www.ncbi.nlm.nih.gov/pubmed/15546602", "http://www.ncbi.nlm.nih.gov/pubmed/17868250", "http://www.ncbi.nlm.nih.gov/pubmed/35130356", "http://www.ncbi.nlm.nih.gov/pubmed/25622669", "http://www.ncbi.nlm.nih.gov/pubmed/31943276"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/17868250", "text": "FN) is diagnosed on the basis of clinical features and specialized tests of small-fiber function because standard nerve conduction studies are normal.", "offsetInBeginSection": 25, "offsetInEndSection": 175, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30968230", "text": "r genetic factors. The main clinical features include neuropathic pain and autonomic disturbance, which are occasionally disclaimed due to outstanding", "offsetInBeginSection": 288, "offsetInEndSection": 438, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15546602", "text": "sis of the clinical features, normal nerve conduction studies (NCS) and abnormal specialized tests of small nerve fibers. Among others, these tests in", "offsetInBeginSection": 340, "offsetInEndSection": 490, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34075618", "text": "gnosed with definite SFN (typical clinical features, normal nerve conduction studies, abnormal epidermal nerve fiber density) from the end of November", "offsetInBeginSection": 341, "offsetInEndSection": 491, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31943276", "text": " investigations, including quantitative sensory testing, intraepidermal nerve fiber density and confocal corneal microscopy. Knowledge of these disord", "offsetInBeginSection": 364, "offsetInEndSection": 514, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25622669", "text": "re the relationship between clinical features, electrophysiology and intraepidermal nerve fiber density (IENFD) in peripheral neuropathy with small fi", "offsetInBeginSection": 18, "offsetInEndSection": 168, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33802768", "text": "wn as SFN. This pathology may be the result of metabolic, toxic, immune-mediated, and/or genetic factors. Small fiber symptoms can be variable and inc", "offsetInBeginSection": 170, "offsetInEndSection": 320, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22570215", "text": "ed by negative sensory symptoms (thermal and pinprick hypoesthesia) reflecting peripheral deafferentation and positive sensory symptoms and signs (bur", "offsetInBeginSection": 43, "offsetInEndSection": 193, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35130356", "text": " most of them request typical clinical features and reduced intra-epidermal nerve fiber density on proximal or distal skin biopsy. Little consensus ha", "offsetInBeginSection": 322, "offsetInEndSection": 472, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23982054", "text": "We conducted the current study to analyze the clinical, immunologic, and neurophysiologic features of primary Sj\u00f6gren syndrome (pSS)-associated sensor", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415c53e690f196b51000012", "type": "factoid", "body": "When was Keytruda approved by the FDA for the treatment of metastatic non-small cell lung cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24573551", "http://www.ncbi.nlm.nih.gov/pubmed/27659911", "http://www.ncbi.nlm.nih.gov/pubmed/27821604", "http://www.ncbi.nlm.nih.gov/pubmed/27920140"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24573551", "text": "as granted on the basis of the high ORRs and durable responses. On November 20, 2013, crizotinib received full approval based on an improvement in pro", "offsetInBeginSection": 1086, "offsetInEndSection": 1236, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27659911", "text": "or patients with metastatic non-small cell lung cancer by the FDA in October, 2015. We present the first case, to the best of our knowledge, of a pati", "offsetInBeginSection": 547, "offsetInEndSection": 697, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27920140", "text": "andomized trials, the FDA approved the anti-PD-L1 agent atezolizumab in October. It is the first PD-L1 inhibitor approved for use in patients with met", "offsetInBeginSection": 49, "offsetInEndSection": 199, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27821604", "text": "In 2015, the FDA approved an unprecedented number of new therapies for non-small cell lung cancer (NSCLC), among them therapies addressing specific ge", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6417949d690f196b51000035", "type": "list", "body": "Which gene therapies are under investigation for Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32542436", "http://www.ncbi.nlm.nih.gov/pubmed/26140505", "http://www.ncbi.nlm.nih.gov/pubmed/26754139", "http://www.ncbi.nlm.nih.gov/pubmed/2663627", "http://www.ncbi.nlm.nih.gov/pubmed/30119719", "http://www.ncbi.nlm.nih.gov/pubmed/30275245", "http://www.ncbi.nlm.nih.gov/pubmed/27594988", "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "http://www.ncbi.nlm.nih.gov/pubmed/19745732", "http://www.ncbi.nlm.nih.gov/pubmed/7804468"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/30119719", "text": "oval of two genetic therapies by the US Food and Drug Administration: eteplirsen for Duchenne muscular dystrophy and nusinersen for spinal muscular at", "offsetInBeginSection": 420, "offsetInEndSection": 570, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32542436", "text": "nt years. Molecular therapies such as direct gene transfer or alternative processing of the disease-specific gene play an important role in this trans", "offsetInBeginSection": 235, "offsetInEndSection": 385, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "text": " stem cell generation and discuss their implications for the study, modeling, and development of cell-based therapies for Duchenne muscular dystrophy.", "offsetInBeginSection": 600, "offsetInEndSection": 750, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7804468", "text": "uromuscular disorders. A number of the viral vector systems, myoblast transfer, and direct injection techniques that are currently under investigation", "offsetInBeginSection": 240, "offsetInEndSection": 390, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30275245", "text": "-specific strategies include nonsense readthrough, exon skipping, gene editing, utrophin modulation, and gene replacement. Other mechanisms include mu", "offsetInBeginSection": 749, "offsetInEndSection": 899, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26140505", "text": "e for the primary defect of this disease. These include dystrophin gene-replacement strategies, genetic modification techniques to restore dystrophin ", "offsetInBeginSection": 1307, "offsetInEndSection": 1457, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2663627", "text": "mmon forms of muscular dystrophy, Duchenne muscular dystrophy and myotonic dystrophy. 5. Supportive therapies for muscular dystrophy patients now incl", "offsetInBeginSection": 741, "offsetInEndSection": 891, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19745732", "text": "gned to repair the primary genetic defect, called 'exon skipping' and 'nonsense codon suppression'.\n\n\nRECENT FINDINGS\nA drug, PTC124, was identified t", "offsetInBeginSection": 193, "offsetInEndSection": 343, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26754139", "text": "oper care to patients according to published guidelines. With mutation-specific therapies under development for DMD, a correct diagnosis is now also i", "offsetInBeginSection": 296, "offsetInEndSection": 446, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27594988", "text": "or DMD are currently available. In this review, we highlight the most advanced therapeutic strategies under investigation as potential DMD treatments.", "offsetInBeginSection": 478, "offsetInEndSection": 628, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f02a82f36125a426000013", "type": "yesno", "body": "Does CIDEB mutation protect from liver disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35939579", "http://www.ncbi.nlm.nih.gov/pubmed/34646017"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34646017", "text": "stinct hepatocyte clones per patient. CIDEB, which regulates lipid droplet metabolism in hepatocytes17-19, and GPAM, which produces storage triacylgly", "offsetInBeginSection": 911, "offsetInEndSection": 1061, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939579", "text": "so found that variants in CIDEB, which encodes a structural protein found in hepatic lipid droplets, had a protective effect. The burden of rare predi", "offsetInBeginSection": 905, "offsetInEndSection": 1055, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939579", "text": " droplets.\n\n\nCONCLUSIONS\nRare germline mutations in CIDEB conferred substantial protection from liver disease. (Funded by Regeneron Pharmaceuticals.).", "offsetInBeginSection": 2112, "offsetInEndSection": 2262, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939579", "text": "h encodes a structural protein found in hepatic lipid droplets, had a protective effect. The burden of rare predicted loss-of-function variants plus m", "offsetInBeginSection": 942, "offsetInEndSection": 1092, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64089b21201352f04a000021", "type": "summary", "body": "Can you summarize the function of CDK9?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30726104", "http://www.ncbi.nlm.nih.gov/pubmed/21200140", "http://www.ncbi.nlm.nih.gov/pubmed/20930849", "http://www.ncbi.nlm.nih.gov/pubmed/21143121", "http://www.ncbi.nlm.nih.gov/pubmed/32901849", "http://www.ncbi.nlm.nih.gov/pubmed/34146121"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20930849", "text": "er, CDK9 also forms a complex with cyclin K, the function of which is less clear. Using a synthetic lethal RNA interference screen in human cells, we ", "offsetInBeginSection": 205, "offsetInEndSection": 355, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32901849", "text": " pathogenic role in various types of cancer, little is known concerning its function in endometrial cancer. Our study was conducted to evaluate the ex", "offsetInBeginSection": 155, "offsetInEndSection": 305, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21200140", "text": "o binds to cyclin K but the function of this CDK9-cyclin K complex is less clear. We and others have recently shown that CDK9 functions directly in ma", "offsetInBeginSection": 302, "offsetInEndSection": 452, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34146121", "text": "coring the need to properly regulate CDK9. Here, I provide an overview of CDK9 function and regulation, with an emphasis on CDK9 dysregulation in huma", "offsetInBeginSection": 810, "offsetInEndSection": 960, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30726104", "text": " established pathogenic role in various cancers, its function in ovarian cancer remains poorly defined. The purpose of this study was to evaluate the ", "offsetInBeginSection": 173, "offsetInEndSection": 323, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21143121", "text": "sulting in novel compounds. The CDK9 inhibitory activity of the derivatives was measured in specific kinase assay and the CDK inhibitory profile of th", "offsetInBeginSection": 700, "offsetInEndSection": 850, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410eead201352f04a000030", "type": "summary", "body": "How does RBM24 control QT interval?", "documents": [], "snippets": []}, {"id": "64105502201352f04a00002d", "type": "yesno", "body": "Is North Star Ambulatory Assessment score a reliable clinical outcome for disease progression assessment in Duchenne Muscular Dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31629611", "http://www.ncbi.nlm.nih.gov/pubmed/35626905", "http://www.ncbi.nlm.nih.gov/pubmed/33978227", "http://www.ncbi.nlm.nih.gov/pubmed/21954141", "http://www.ncbi.nlm.nih.gov/pubmed/20634072", "http://www.ncbi.nlm.nih.gov/pubmed/28648683", "http://www.ncbi.nlm.nih.gov/pubmed/23909763"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23909763", "text": " However, in Duchenne muscular dystrophy (DMD), identifying changes in function is not straightforward. In this study, we use Rasch-transformed data t", "offsetInBeginSection": 184, "offsetInEndSection": 334, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21954141", "text": "ur study indicates that the North Star Ambulatory Assessment is practical and reliable. It takes only 10 minutes to perform and incorporates both univ", "offsetInBeginSection": 911, "offsetInEndSection": 1061, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33978227", "text": "INTRODUCTION\nThere is a need for reliable and properly validated outcome measures in Duchenne muscular dystrophy, both to monitor functional impairmen", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35626905", "text": " (-12 months) to video assessment was 2.0 (2.8SD).\n\n\nCONCLUSION\nThe results from the study suggest that video NSAA is partially feasible and reliable.", "offsetInBeginSection": 1115, "offsetInEndSection": 1265, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31629611", "text": "Our results showed North Star Ambulatory Assessment scores progressively increased with age. The largest increase was observed between age 3 and 4 yea", "offsetInBeginSection": 381, "offsetInEndSection": 531, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20634072", "text": "n daily regimen. The scores on the North Star assessment ranged from 6/34 to 34/34. The distance on the 6-minute walk test ranged from 127 to 560.6 m.", "offsetInBeginSection": 723, "offsetInEndSection": 873, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28648683", "text": "ne muscular dystrophy (p\u2009=\u20090.005). North Star Ambulatory Assessment in Brazilian Portuguese is a reliable and valid instrument to measure functional c", "offsetInBeginSection": 1382, "offsetInEndSection": 1532, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f032caf36125a42600001a", "type": "summary", "body": "What is the mechanism of action of rilzabrutinib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34631841", "http://www.ncbi.nlm.nih.gov/pubmed/35417637", "http://www.ncbi.nlm.nih.gov/pubmed/27324312", "http://www.ncbi.nlm.nih.gov/pubmed/35301810", "http://www.ncbi.nlm.nih.gov/pubmed/33674445", "http://www.ncbi.nlm.nih.gov/pubmed/33942286"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35417637", "text": "nisms of action: decreased macrophage (Fc\u03b3 receptor)-mediated platelet destruction and reduced production of pathogenic autoantibodies.\n\n\nMETHODS\nIn a", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33942286", "text": "id clinical activity in pemphigus vulgaris. These data suggest that BTK inhibition may be a promising treatment strategy and support further investiga", "offsetInBeginSection": 1742, "offsetInEndSection": 1892, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33674445", "text": "ses. We examined the pharmacodynamic profile of rilzabrutinib and its preclinical mechanisms of action. In addition to potent and selective BTK enzyme", "offsetInBeginSection": 344, "offsetInEndSection": 494, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312", "text": "nd the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear. Many (but not all) ex vi", "offsetInBeginSection": 256, "offsetInEndSection": 406, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35301810", "text": "elevant supratherapeutic dose of rilzabrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, and evaluate potential effects of therapeutic and supr", "offsetInBeginSection": 43, "offsetInEndSection": 193, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35417637", "text": "\n\nCONCLUSIONS\nRilzabrutinib was active and associated with only low-level toxic effects at all dose levels. The dose of 400 mg twice daily was identif", "offsetInBeginSection": 1877, "offsetInEndSection": 2027, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33674445", "text": "stantial disease control. Rilzabrutinib is characterized by reversible covalent BTK binding, long BTK residence time with low systemic exposure, and m", "offsetInBeginSection": 1465, "offsetInEndSection": 1615, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35301810", "text": ", or moxifloxacin (positive control). Primary objectives: part A - pharmacokinetics (PK) of rilzabrutinib \u00b1 ritonavir, safety, and optimal dose for Pa", "offsetInBeginSection": 660, "offsetInEndSection": 810, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34631841", "text": "\u03bcM). Conclusion: Remibrutinib and rilzabrutinib inhibit Btk-dependent pathways of platelet aggregation upon GPVI, VWF/GPIb, and Fc\u03b3RIIA activation. Re", "offsetInBeginSection": 1650, "offsetInEndSection": 1800, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33942286", "text": "zabrutinib alone, or with much lower CS doses than usual, was safe, with rapid clinical activity in pemphigus vulgaris. These data suggest that BTK in", "offsetInBeginSection": 1666, "offsetInEndSection": 1816, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "641368ee201352f04a00003c", "type": "list", "body": "What are the  types/categories of adult diffuse gliomas.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36299937", "http://www.ncbi.nlm.nih.gov/pubmed/35578106", "http://www.ncbi.nlm.nih.gov/pubmed/35267601", "http://www.ncbi.nlm.nih.gov/pubmed/32640746", "http://www.ncbi.nlm.nih.gov/pubmed/34729052", "http://www.ncbi.nlm.nih.gov/pubmed/30937703", "http://www.ncbi.nlm.nih.gov/pubmed/36428772", "http://www.ncbi.nlm.nih.gov/pubmed/35599404", "http://www.ncbi.nlm.nih.gov/pubmed/35562130"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34729052", "text": "sion, and 1p/19q co-deletion detection in adult diffuse gliomas (Grade II, III, and IV) and to correlate them with clinicopathological and histopathol", "offsetInBeginSection": 609, "offsetInEndSection": 759, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36299937", "text": "vide into isocitrate dehydrogenase (IDH)-mutant astrocytoma, IDH-mutant and 1p/19q-codeleted oligodendroglioma, and IDH-wildtype glioblastoma. The T2-", "offsetInBeginSection": 198, "offsetInEndSection": 348, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35267601", "text": " (WHO) classifies gliomas as adult-type diffuse gliomas or circumscribed astrocytic gliomas depending on their histology and molecular features. Spina", "offsetInBeginSection": 160, "offsetInEndSection": 310, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35562130", "text": "include astrocytoma, isocitrate dehydrogenase (IDH)-mutant, oligodendroglioma, IDH-mutant and 1p/19q codeleted, and glioblastoma, IDH-wildtype. This r", "offsetInBeginSection": 293, "offsetInEndSection": 443, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32640746", "text": "hese changes has been the division of adult astrocytomas into IDH-wildtype and IDH-mutant categories in addition to histologic grade as part of the ma", "offsetInBeginSection": 494, "offsetInEndSection": 644, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30937703", "text": "eous group of tumors of the central nervous system that vary greatly in histology and prognosis. A significant advance during the last decade has been", "offsetInBeginSection": 38, "offsetInEndSection": 188, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35599404", "text": "portant revisions is the division of the classification into adult-type and pediatric-type diffuse gliomas, and the latter is further divided into ped", "offsetInBeginSection": 510, "offsetInEndSection": 660, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36428772", "text": " methylation-based classification works and list the methylation-based tumour types and subclasses for adult and paediatric diffuse gliomas. The benef", "offsetInBeginSection": 292, "offsetInEndSection": 442, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34729052", "text": " which could be useful for the evaluation of prognosis, especially Grade III and II. Although the immunohistochemical approach does not replace geneti", "offsetInBeginSection": 1595, "offsetInEndSection": 1745, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35578106", "text": "lar features. Many tumors have also been reconceptualized into new \"supercategories,\" including adult-type diffuse gliomas, pediatric-type diffuse low", "offsetInBeginSection": 446, "offsetInEndSection": 596, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415ca99690f196b51000019", "type": "yesno", "body": "Have chimeric antigen receptor (CAR)-T cell therapies been approved for the treatment of B cell malignancies?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29499327", "http://www.ncbi.nlm.nih.gov/pubmed/32402724", "http://www.ncbi.nlm.nih.gov/pubmed/33792221", "http://www.ncbi.nlm.nih.gov/pubmed/34040345", "http://www.ncbi.nlm.nih.gov/pubmed/33463538", "http://www.ncbi.nlm.nih.gov/pubmed/33689570"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33792221", "text": " are currently under investigation. However, none of these current autologous therapies have been approved, and despite high overall response rates ac", "offsetInBeginSection": 525, "offsetInEndSection": 675, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32402724", "text": "Chimeric antigen receptor (CAR) T cell therapy is currently approved for treatment of refractory B-cell malignancies. Response rates in these diseases", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33689570", "text": "t allows the hybrid cell to target antigens of interest. CAR T-cell therapy has been approved to treat various hematologic malignancies, including rel", "offsetInBeginSection": 229, "offsetInEndSection": 379, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33463538", "text": "atologic malignancies, leading to the US Food and Drug Administration approval of two CAR T cell-based therapies for the treatment of B cell acute lym", "offsetInBeginSection": 85, "offsetInEndSection": 235, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34040345", "text": "nd plasma cell malignancies, with five CAR T cell products now approved by the US Food and Drug Administration (FDA). However, CAR T cell therapies fo", "offsetInBeginSection": 107, "offsetInEndSection": 257, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29499327", "text": "cell malignancies, Kymriah and Yescarta, have recently been approved by the Food and Drug Administration. The administration of CAR T cells is a compl", "offsetInBeginSection": 86, "offsetInEndSection": 236, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64178e4b690f196b51000022", "type": "yesno", "body": "Is golodirsen effective for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32139505", "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "http://www.ncbi.nlm.nih.gov/pubmed/34788571", "http://www.ncbi.nlm.nih.gov/pubmed/12843632", "http://www.ncbi.nlm.nih.gov/pubmed/19517771", "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "http://www.ncbi.nlm.nih.gov/pubmed/30544588"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19517771", "text": "ing gene transfer strategies have been conducted, but no effective treatment has been established. Two plausible ways have been proposed. One is the i", "offsetInBeginSection": 294, "offsetInEndSection": 444, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32139505", "text": "sured by Western blot and immunohistochemistry.\n\n\nCONCLUSION\nGolodirsen was well-tolerated; muscle biopsies from golodirsen-treated patients showed in", "offsetInBeginSection": 1501, "offsetInEndSection": 1651, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "text": "r dystrophy is a lethal neuromuscular disease that currently has no effective therapy. Transgenic overexpression of the alpha7 integrin in mdx/utrn(-/", "offsetInBeginSection": 16, "offsetInEndSection": 166, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "text": "es, most commonly as limb-girdle muscular dystrophy 2I. There is no effective therapy available. Glucocorticoid steroids have become the standard trea", "offsetInBeginSection": 137, "offsetInEndSection": 287, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12843632", "text": "dystrophin, a 427-kDa cytoskeletal protein, but the effective therapeutic drug is presently unavailable. We previously reported that a trypsin-like pr", "offsetInBeginSection": 73, "offsetInEndSection": 223, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34788571", "text": "m of this Phase 1/2, 2-part, multicenter trial was to report clinical safety and efficacy of long-term golodirsen treatment among ambulatory patients ", "offsetInBeginSection": 6, "offsetInEndSection": 156, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32139505", "text": "SSIFICATION OF EVIDENCE\nThis study provides Class I evidence that golodirsen is safe and Class IV evidence that it induces exon skipping and novel dys", "offsetInBeginSection": 1798, "offsetInEndSection": 1948, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32139505", "text": "rsen-treated patients with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping.\n\n\nMETHODS\nPart 1 was a randomized, double-blind, placebo-co", "offsetInBeginSection": 99, "offsetInEndSection": 249, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "text": "ive degeneration of skeletal and cardiac muscles. Currently, there is no effective therapy for this disorder. However, the technology of cell reprogra", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f043e4f36125a426000023", "type": "yesno", "body": "Is Baricitinib effective for Alopecia Areata?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26137574", "http://www.ncbi.nlm.nih.gov/pubmed/31930807", "http://www.ncbi.nlm.nih.gov/pubmed/36239359", "http://www.ncbi.nlm.nih.gov/pubmed/34090959"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/31930807", "text": "e safety and efficacy of these medications. If indeed these treatments will prove to be effective and safe, they might become the first FDA-approved t", "offsetInBeginSection": 933, "offsetInEndSection": 1083, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34090959", "text": "GROUND\nThere are no treatments approved by the Food and Drug Administration for alopecia areata.\n\n\nOBJECTIVE\nTo evaluate the efficacy and safety of ba", "offsetInBeginSection": 4, "offsetInEndSection": 154, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26137574", "text": "ovement during baricitinib treatment.\n\n\nINTERPRETATION\nBaricitinib may be an effective treatment for AA and warrants further investigation in clinical", "offsetInBeginSection": 851, "offsetInEndSection": 1001, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36239359", "text": "% CI [2.38, 9.66], p .0001).\n\n\nCONCLUSION\nWhen compared to placebo, baricitinib is an effective and well-tolerated medication for the treatment of AA.", "offsetInBeginSection": 1237, "offsetInEndSection": 1387, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64137616201352f04a000041", "type": "yesno", "body": "Anemia is not associated with chronic kidney failure", "documents": [], "snippets": []}, {"id": "6415bc8d690f196b5100000f", "type": "factoid", "body": "What is the estimated reduction in time when using online genetic counseling?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30121717"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/30121717", "text": "y from a high school course (37.3%), college course (28.1%), or online (11.5%). Familiarity was associated with factors such as female gender (p\u2009=\u20090.0", "offsetInBeginSection": 658, "offsetInEndSection": 808, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64163660690f196b5100001d", "type": "yesno", "body": "Is deflazacort more efficient than prednisone/prednisolone for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8521761", "http://www.ncbi.nlm.nih.gov/pubmed/8882570", "http://www.ncbi.nlm.nih.gov/pubmed/34440496", "http://www.ncbi.nlm.nih.gov/pubmed/30028519", "http://www.ncbi.nlm.nih.gov/pubmed/33104035", "http://www.ncbi.nlm.nih.gov/pubmed/19488064", "http://www.ncbi.nlm.nih.gov/pubmed/11038071", "http://www.ncbi.nlm.nih.gov/pubmed/20581335", "http://www.ncbi.nlm.nih.gov/pubmed/35381069"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34440496", "text": "iduals with DMD undergoing pharmacotherapies with Deflazacort achieved lower HRV, akin to individuals with DMD without any medications, as demonstrate", "offsetInBeginSection": 978, "offsetInEndSection": 1128, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11038071", "text": "cort slows the progress of Duchenne muscular dystrophy (DMD) with fewer side effects than prednisone. In mdx mice, deflazacort treatment augments repa", "offsetInBeginSection": 7, "offsetInEndSection": 157, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30028519", "text": "stable regimens throughout study. This post hoc analysis compares efficacy and safety for deflazacort and prednisone/prednisolone in the placebo arm.\n", "offsetInBeginSection": 173, "offsetInEndSection": 323, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8882570", "text": "e muscular dystrophy (DMD). Deflazacort (DFC) is supposed to have fewer side effects than prednisone (PRED). An ongoing double blind multicenter study", "offsetInBeginSection": 116, "offsetInEndSection": 266, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064", "text": "ndpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects. As mechanisms of improvement and side effect differen", "offsetInBeginSection": 52, "offsetInEndSection": 202, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8521761", "text": "es and psychiatric disorders. In general, deflazacort appears to have less effect than prednisone on parameters which may be associated with the devel", "offsetInBeginSection": 1192, "offsetInEndSection": 1342, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33104035", "text": " Glucocorticoid steroids such as prednisone and deflazacort are recommended for treating Duchenne Muscular Dystrophy where their use prolongs ambulation and life expectancy", "offsetInBeginSection": 99, "offsetInEndSection": 271, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20581335", "text": "t corticosteroids be offered (prednisone 0.75 mg/kg/d and deflazacort 0.9 mg/kg/d) as treatment. Recent reports emphasize that longer term treatment w", "offsetInBeginSection": 324, "offsetInEndSection": 474, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35381069", "text": "leted the trial. Both daily prednisone and daily deflazacort were more effective than intermittent prednisone for the primary outcome (P\u2009<\u2009.001 for da", "offsetInBeginSection": 1497, "offsetInEndSection": 1647, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6402bc2d201352f04a000005", "type": "list", "body": "What are the targets of Mosunetuzumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21440000", "http://www.ncbi.nlm.nih.gov/pubmed/35803286", "http://www.ncbi.nlm.nih.gov/pubmed/17848073", "http://www.ncbi.nlm.nih.gov/pubmed/35947358", "http://www.ncbi.nlm.nih.gov/pubmed/35152430", "http://www.ncbi.nlm.nih.gov/pubmed/12135991", "http://www.ncbi.nlm.nih.gov/pubmed/34914545", "http://www.ncbi.nlm.nih.gov/pubmed/32859946"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34914545", "text": "PURPOSE\nMosunetuzumab is a bispecific antibody targeting CD20 and CD3 that redirects T cells to engage and eliminate malignant B cells and is being de", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32859946", "text": "d blinatumomab), including the dynamics of B- and T-lymphocytes in circulation, lymphoid tissues, and tumor. The model was developed and validated usi", "offsetInBeginSection": 530, "offsetInEndSection": 680, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35947358", "text": "ody, is being developed by Roche for the treatment of relapsed or refractory follicular lymphoma. Mosunetuzumab was recently conditionally approved in", "offsetInBeginSection": 76, "offsetInEndSection": 226, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12135991", "text": "ent Targets. The targets for health are based on improvements in infant, child and maternal mortality. Progress towards these goals will be used to as", "offsetInBeginSection": 132, "offsetInEndSection": 282, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35152430", "text": "roadly classified into those which strive to modify bile, inflammation, cell survival, or fibrosis. In bile, shrinking the size of the bile acid pool ", "offsetInBeginSection": 645, "offsetInEndSection": 795, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34914545", "text": "days 1, 8, and 15 (group B), for eight or 17 cycles on the basis of tumor response.\n\n\nRESULTS\nTwo hundred thirty patients were enrolled. Doses up to 2", "offsetInBeginSection": 662, "offsetInEndSection": 812, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32859946", "text": " T-cell dependent bispecific antibody that binds CD3 and CD20 to drive T-cell mediated B-cell killing, is currently being tested in non-Hodgkin lympho", "offsetInBeginSection": 16, "offsetInEndSection": 166, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35803286", "text": "ging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells. In a phase 1 study, mosunetuzumab was well tolerated and ac", "offsetInBeginSection": 52, "offsetInEndSection": 202, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21440000", "text": "e Th1 and Th2 inflammation precipitating symptoms. In both, innate and adaptive immunities are involved, providing a series of potential targets for t", "offsetInBeginSection": 450, "offsetInEndSection": 600, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17848073", "text": " of extensive human vaccination, each of these approaches target post-spillover events and none of these avenues of research will have the slightest i", "offsetInBeginSection": 1056, "offsetInEndSection": 1206, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64144200201352f04a000043", "type": "yesno", "body": "Is anaphylaxis a results of mast cell activation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32709306", "http://www.ncbi.nlm.nih.gov/pubmed/35080312", "http://www.ncbi.nlm.nih.gov/pubmed/24948367", "http://www.ncbi.nlm.nih.gov/pubmed/27906487", "http://www.ncbi.nlm.nih.gov/pubmed/22744266", "http://www.ncbi.nlm.nih.gov/pubmed/25240785", "http://www.ncbi.nlm.nih.gov/pubmed/31011586", "http://www.ncbi.nlm.nih.gov/pubmed/2661436", "http://www.ncbi.nlm.nih.gov/pubmed/16804320", "http://www.ncbi.nlm.nih.gov/pubmed/20526344"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27906487", "text": "d in the amplification of the mast cell response during anaphylaxis are unclear. Mouse models of anaphylaxis demonstrate the critical involvement of n", "offsetInBeginSection": 33, "offsetInEndSection": 183, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22744266", "text": "hylaxis in 22-49%. In addition, monoclonal mast cell activation syndrome has been described presenting with anaphylaxis, especially in patients with h", "offsetInBeginSection": 77, "offsetInEndSection": 227, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25240785", "text": "ntrol subjects. The severity of anaphylaxis was associated with mast cell degranulation, increased plasma heparin levels, the intensity of contact sys", "offsetInBeginSection": 1253, "offsetInEndSection": 1403, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31011586", "text": " types. Finally, we discuss the possible reasons for the mast cell to utilize compound exocytosis during anaphylaxis, the conflicting evidence in diff", "offsetInBeginSection": 1017, "offsetInEndSection": 1167, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20526344", "text": "arepsilonRI) on mast cells. However, the regulatory mechanism of mast cell activation is not completely understood. Here we identify an immunoglobulin", "offsetInBeginSection": 169, "offsetInEndSection": 319, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35080312", "text": "w clinical entities, such as the \u03b1-gal anaphylaxis. Anaphylaxis results from the massive activation of the mast cells (MCs). Thus, it is also necessar", "offsetInBeginSection": 465, "offsetInEndSection": 615, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24948367", "text": "ed that mast cell activation and anaphylaxis are negatively regulated by AMP-activated protein kinase (AMPK). However, little is known about the relat", "offsetInBeginSection": 342, "offsetInEndSection": 492, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2661436", "text": "s not affected. Calcium-independent early activation events in mast cell anaphylaxis indicated on inhibitory influence of PK-treatment. Inhibition of ", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16804320", "text": "hese results indicate that neither MBL nor activation of the complement cascade is crucial for the induction of anaphylaxis. In contrast mast cell act", "offsetInBeginSection": 1227, "offsetInEndSection": 1377, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32709306", "text": "SIONS\nOur study suggests that the mast cell activation test can be used to diagnose IgE/Fc\u03b5RI-dependent immediate drug hypersensitivity reactions. It ", "offsetInBeginSection": 1495, "offsetInEndSection": 1645, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415c6b6690f196b51000015", "type": "list", "body": "On which two clinical trials was the approval of Keytruda based?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28235882", "http://www.ncbi.nlm.nih.gov/pubmed/32272501", "http://www.ncbi.nlm.nih.gov/pubmed/28835513"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/32272501", "text": " Merkel cell carcinoma (MCC). Approval was based on Cancer Immunotherapy Trials Network protocol 9, also known as KEYNOTE-017 (NCT02267603), a multice", "offsetInBeginSection": 232, "offsetInEndSection": 382, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28835513", "text": "ificant improvement in PFS (HR 0.50; 95% CI: 0.37-0.68; p\u2009<\u2009.001). In KEYNOTE-010, patients with disease progression on or after platinum-containing c", "offsetInBeginSection": 1396, "offsetInEndSection": 1546, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28235882", "text": "s in 89 patients enrolled in a randomized, multicenter, open-label, dose-finding, and activity-estimating phase 1 trial. The overall response rate (OR", "offsetInBeginSection": 443, "offsetInEndSection": 593, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64178e34690f196b51000021", "type": "yesno", "body": "Is viltolarsen effective for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33285037", "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "http://www.ncbi.nlm.nih.gov/pubmed/30796500", "http://www.ncbi.nlm.nih.gov/pubmed/12843632", "http://www.ncbi.nlm.nih.gov/pubmed/32453377", "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "http://www.ncbi.nlm.nih.gov/pubmed/36401022", "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "http://www.ncbi.nlm.nih.gov/pubmed/30544588"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "text": "se of mortality among Duchenne muscular dystrophy patients and lacks effective therapies. Phosphodiesterase type 5 is implicated in dystrophic patholo", "offsetInBeginSection": 42, "offsetInEndSection": 192, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32453377", "text": "80 mg/kg per week: mean [range] 5.9% [1.1-14.4] of normal). Viltolarsen was well tolerated; no treatment-emergent adverse events required dose reducti", "offsetInBeginSection": 1685, "offsetInEndSection": 1835, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "text": "r dystrophy is a lethal neuromuscular disease that currently has no effective therapy. Transgenic overexpression of the alpha7 integrin in mdx/utrn(-/", "offsetInBeginSection": 16, "offsetInEndSection": 166, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12843632", "text": "dystrophin, a 427-kDa cytoskeletal protein, but the effective therapeutic drug is presently unavailable. We previously reported that a trypsin-like pr", "offsetInBeginSection": 73, "offsetInEndSection": 223, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30796500", "text": "ith Duchenne muscular dystrophy experienced severe acute heart failure triggered by pneumonia. Levosimendan was effective in improving heart function.", "offsetInBeginSection": 264, "offsetInEndSection": 414, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "text": "es, most commonly as limb-girdle muscular dystrophy 2I. There is no effective therapy available. Glucocorticoid steroids have become the standard trea", "offsetInBeginSection": 137, "offsetInEndSection": 287, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36401022", "text": "runcated but functional form of dystrophin. It can treat approximately 8-10% of the DMD patient population.\u00a0This paper aims to summarize the developme", "offsetInBeginSection": 786, "offsetInEndSection": 936, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32453377", "text": "Conclusions and Relevance\nSystemic treatment of participants with DMD with viltolarsen induced de novo dystrophin production, and clinical improvement", "offsetInBeginSection": 2378, "offsetInEndSection": 2528, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33285037", "text": "cleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with Duchenne muscular dystrophy (DMD). ", "offsetInBeginSection": 48, "offsetInEndSection": 198, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "text": "ive degeneration of skeletal and cardiac muscles. Currently, there is no effective therapy for this disorder. However, the technology of cell reprogra", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640410d1201352f04a000012", "type": "summary", "body": "What is Wilkie's syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21276386", "http://www.ncbi.nlm.nih.gov/pubmed/9455097", "http://www.ncbi.nlm.nih.gov/pubmed/35047254", "http://www.ncbi.nlm.nih.gov/pubmed/29673098", "http://www.ncbi.nlm.nih.gov/pubmed/19066831", "http://www.ncbi.nlm.nih.gov/pubmed/30254733", "http://www.ncbi.nlm.nih.gov/pubmed/34401041", "http://www.ncbi.nlm.nih.gov/pubmed/21365426", "http://www.ncbi.nlm.nih.gov/pubmed/33083170", "http://www.ncbi.nlm.nih.gov/pubmed/28100055"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33083170", "text": "Superior mesenteric artery syndrome, or Wilkie's syndrome, is an unexpected cause of upper gastrointestinal tract obstruction. The exact incidence of ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28100055", "text": "Superior mesenteric artery syndrome, also Wilkie's syndrome, is an uncommon cause of upper intestinal obstruction. It includes compression of the thir", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21365426", "text": "Wilkie's syndrome (superior mesenteric artery syndrome) is a rare cause of obstruction to the third part of duodenum due to compression between the su", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29673098", "text": "Superior mesenteric artery syndrome, also known as Wilkie's syndrome, is a rare cause of proximal duodenum obstruction in children. Here, we describe ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9455097", "text": "Wilkie's syndrome is a rare disease that should be considered in the differential diagnosis of upper abdominal discomfort and weight loss. Compression", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19066831", "text": "The superior mesenteric artery syndrome--also known as Wilkie's syndrome or as arteriomesenteric obstruction of the duodenum--is a rare condition of u", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21276386", "text": "Wilkie's syndrome is a rare variant of small intestinal obstruction resulting from compression of third part of the duodenum by the superior mesenteri", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30254733", "text": "Wilkie's syndrome is a rare cause of duodenal obstruction that can easily be missed at clinical practice. It is characterized by nausea, abdominal pai", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35047254", "text": "c and with progressive weight gain. Wilkie's syndrome is a rare form of intestinal obstruction, which is commonly disregarded. Its non-specific sympto", "offsetInBeginSection": 1520, "offsetInEndSection": 1670, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34401041", "text": "Wilkie's Syndrome is a very rare disease caused by reduction of aorto-mesenteric space with consequent duodenum compression. It can combine with left ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "641461bb201352f04a000046", "type": "summary", "body": "What is a PROTAC?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32164504", "http://www.ncbi.nlm.nih.gov/pubmed/36139095", "http://www.ncbi.nlm.nih.gov/pubmed/33010159", "http://www.ncbi.nlm.nih.gov/pubmed/36300631", "http://www.ncbi.nlm.nih.gov/pubmed/32404196", "http://www.ncbi.nlm.nih.gov/pubmed/34285415", "http://www.ncbi.nlm.nih.gov/pubmed/32082969", "http://www.ncbi.nlm.nih.gov/pubmed/34081921", "http://www.ncbi.nlm.nih.gov/pubmed/26593377", "http://www.ncbi.nlm.nih.gov/pubmed/33160761"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33160761", "text": "Proteolysis targeting chimera (PROTAC), hijacking protein of interest (POI) and recruiting E3 ligase for target degradation via the ubiquitin-proteaso", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36300631", "text": "Proteolysis targeting chimeras (PROTACs), which harness the ubiquitin-proteasome system to selectively induce targeted protein degradation, represent ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34081921", "text": "Proteolysis-targeting chimeras (PROTACs) represent a new direction in small-molecule therapeutics whereby a heterobifunctional linker to a protein of ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32082969", "text": "teins and aggregated proteins is a challenging goal. PROTAC proteolysis-targeting chimaera (PROTAC) technology may be the solution, considering its ab", "offsetInBeginSection": 49, "offsetInEndSection": 199, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34285415", "text": "Proteolysis-targeting chimeras (PROTACs) are an emerging drug modality that may offer new opportunities to circumvent some of the limitations associat", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32164504", "text": "PROTAC (Proteolysis Targeting Chimera) degraders based on protein knockdown technology are now suggested as a novel option for the treatment of variou", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26593377", "text": "Proteolysis Targeting Chimera (PROTAC) technology is a rapidly emerging alternative therapeutic strategy with the potential to address many of the cha", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33010159", "text": "Proteolysis-targeting chimeras (PROTACs), which selectively degrade targeted proteins by the ubiquitin-proteasome system, have emerged as a novel ther", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32404196", "text": "Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. A bifunctional PROTAC molecule c", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36139095", "text": "PROTAC (proteolysis-targeting chimeras), which selectively degrades target proteins, has become the most popular technology for drug development in re", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410f839201352f04a000032", "type": "yesno", "body": "Can the concept of digital twins be applied in Precision Nutrition?", "documents": [], "snippets": []}, {"id": "63eef6edf36125a42600000d", "type": "summary", "body": "What is the mechanism of action of Teclistamab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34388396", "http://www.ncbi.nlm.nih.gov/pubmed/32956453", "http://www.ncbi.nlm.nih.gov/pubmed/35661166", "http://www.ncbi.nlm.nih.gov/pubmed/35749004"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34388396", "text": "b is a bispecific antibody that binds BCMA and CD3 to redirect T cells to multiple myeloma cells. The aim of the MajesTEC-1 study was to evaluate the ", "offsetInBeginSection": 162, "offsetInEndSection": 312, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32956453", "text": "lthy human whole blood, teclistamab mediated dose-dependent lysis of H929 cells and activation of T cells. Antitumor activity of teclistamab was also ", "offsetInBeginSection": 1020, "offsetInEndSection": 1170, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35749004", "text": "turation antigen \u00d7 CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies.\n\n\nOBJECTIV", "offsetInBeginSection": 50, "offsetInEndSection": 200, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35661166", "text": " grade 1 or 2).\n\n\nCONCLUSIONS\nTeclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refra", "offsetInBeginSection": 1934, "offsetInEndSection": 2084, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35661166", "text": "T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells", "offsetInBeginSection": 28, "offsetInEndSection": 196, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32956453", "text": "fic antibody (teclistamab [JNJ-64007957]) to recruit and activate T cells to kill BCMA-expressing MM cells. Teclistamab induced cytotoxicity of BCMA+ ", "offsetInBeginSection": 306, "offsetInEndSection": 456, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35749004", "text": " recommended Phase II dose (RP2D). With active doses, exposure was maintained above the mean EC90. All patients who responded to the RP2D of teclistam", "offsetInBeginSection": 1295, "offsetInEndSection": 1445, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640c8309201352f04a000024", "type": "list", "body": "The diagnosis of cholestasis is based on the elevations seen in what liver function tests?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/108658", "http://www.ncbi.nlm.nih.gov/pubmed/7872869", "http://www.ncbi.nlm.nih.gov/pubmed/28106928", "http://www.ncbi.nlm.nih.gov/pubmed/30688121", "http://www.ncbi.nlm.nih.gov/pubmed/2372276", "http://www.ncbi.nlm.nih.gov/pubmed/1858028", "http://www.ncbi.nlm.nih.gov/pubmed/36426309"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/30688121", "text": "cy is a diagnosis of exclusion and presents with unexplained pruritus, abnormal liver function tests, and increased serum bile acid levels, particular", "offsetInBeginSection": 35, "offsetInEndSection": 185, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36426309", "text": " protein, and total bile acids were among the biochemical predictors. Blood tests that confirm obstetric cholestasis should alter the course of treatm", "offsetInBeginSection": 1270, "offsetInEndSection": 1420, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2372276", "text": " patients with markedly elevated serum bilirubin concentration, alkaline phosphatase and aspartate transaminase levels. Extrahepatic biliary obstructi", "offsetInBeginSection": 235, "offsetInEndSection": 385, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7872869", "text": " proposed to help in differentiating these two entities, among which liver biopsy is the most frequently employed, and ultrasonography one of the most", "offsetInBeginSection": 336, "offsetInEndSection": 486, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1858028", "text": "unted but did not obliterate normal sequential elevations in H-ras found in control livers. The expression of c-myc was inhibited threefold with chole", "offsetInBeginSection": 1210, "offsetInEndSection": 1360, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1858028", "text": "cholestasis without cirrhosis. Despite early elevations of total hepatic DNA and RNA values, cholestatic livers demonstrated a significant threefold s", "offsetInBeginSection": 600, "offsetInEndSection": 750, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/108658", "text": "ter discontinuation of TPN, which suggests a causal relationship. Hepatic microscopy was abnormal in 12 of 14 infants examined. The main features were", "offsetInBeginSection": 422, "offsetInEndSection": 572, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28106928", "text": " elevations of serum alkaline phosphatase and gamma-glutamyltransferases levels exceed those of alanine and aspartate aminotransferases. With prolonge", "offsetInBeginSection": 221, "offsetInEndSection": 371, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30688121", "text": "red in both groups and correlation analysis were performed between the YKL-40 and other liver function tests. Serum YKL-40 concentrations were higher ", "offsetInBeginSection": 507, "offsetInEndSection": 657, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415c599690f196b51000013", "type": "factoid", "body": "Which company produces Keytruda?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26631501", "http://www.ncbi.nlm.nih.gov/pubmed/30547369"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/30547369", "text": "e for Health and Care Excellence (NICE) invited the manufacturer (Merck Sharp & Dohme) of pembrolizumab (Keytruda\u00ae) to submit evidence of its clinical", "offsetInBeginSection": 79, "offsetInEndSection": 229, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26631501", "text": "lopment of checkpoint inhibitors that target the PD-1/PD-L1 pathway. Pembrolizumab (MK-3475, lambrolizumab, Keytruda(\u00ae)) is a PD-1 inhibitor that has ", "offsetInBeginSection": 111, "offsetInEndSection": 261, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64040edf201352f04a000011", "type": "yesno", "body": "Based on clinical trial data, can pioglitazone delay cognitive impairment for people at risk for Alzheimer's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35841241", "http://www.ncbi.nlm.nih.gov/pubmed/34146512"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34146512", "text": "e non-futility threshold.\n\n\nINTERPRETATION\nPioglitazone did not delay the onset of mild cognitive impairment. The biomarker algorithm demonstrated a 3", "offsetInBeginSection": 3689, "offsetInEndSection": 3839, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35841241", "text": "ruit enriched cohorts of predicted decliners can reduce clinical trial sample sizes by as much as 51% while maintaining the same detection power.\n\n\nCO", "offsetInBeginSection": 2140, "offsetInEndSection": 2290, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414638c201352f04a000047", "type": "factoid", "body": "Cereblon (CRBN)  has been identified as the target for what type of drug?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23565715", "http://www.ncbi.nlm.nih.gov/pubmed/32333926", "http://www.ncbi.nlm.nih.gov/pubmed/33777938", "http://www.ncbi.nlm.nih.gov/pubmed/22552008", "http://www.ncbi.nlm.nih.gov/pubmed/32865967", "http://www.ncbi.nlm.nih.gov/pubmed/25016816", "http://www.ncbi.nlm.nih.gov/pubmed/34033753", "http://www.ncbi.nlm.nih.gov/pubmed/24328678", "http://www.ncbi.nlm.nih.gov/pubmed/22966948"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34033753", "text": "ted with intellectual disability, was identified as primary target of thalidomide. Accumulating evidence has shown that CRBN is a substrate receptor o", "offsetInBeginSection": 56, "offsetInEndSection": 206, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33777938", "text": "d previously demonstrated that cereblon (CRBN) is the target of thalidomide embryopathy and acts as a substrate receptor for the E3 ubiquitin ligase c", "offsetInBeginSection": 172, "offsetInEndSection": 322, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22966948", "text": "dy recently identified cereblon (CRBN) as a primary target of thalidomide teratogenicity. Subsequently it was demonstrated that CRBN is also required ", "offsetInBeginSection": 333, "offsetInEndSection": 483, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32333926", "text": "ullin-ring E3 ubiquitin ligase (CRL), is a major target protein of immunomodulatory drugs. An earlier study demonstrated that CRBN directly interacts ", "offsetInBeginSection": 43, "offsetInEndSection": 193, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23565715", "text": "Cereblon (CRBN) has recently been identified as a target for immunomodulatory drugs (IMiDs) and its downregulation has been linked to resistance to le", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24328678", "text": "Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex, CRL4(C", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22552008", "text": "eblon (CRBN) has been identified as the primary teratogenic target of thalidomide. Our studies demonstrate that thalidomide, lenalidomide and another ", "offsetInBeginSection": 163, "offsetInEndSection": 313, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33777938", "text": " that CRBN-based small-molecule compounds regulating the proliferation of neural stem cells may be developed for application in regenerative medicine.", "offsetInBeginSection": 1622, "offsetInEndSection": 1772, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32865967", "text": "tly being explored as a therapeutic target for the treatment of acute myeloid leukemia. Molecular docking studies with CRBN and GSPT1 followed by anal", "offsetInBeginSection": 744, "offsetInEndSection": 894, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25016816", "text": "BN), has been identified as a direct molecular target for anti-neoplastic activities of IMiDs. CRBN has also been shown to be involved in IMiDs-mediat", "offsetInBeginSection": 543, "offsetInEndSection": 693, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f9cdb033942b094c000012", "type": "yesno", "body": "Does silencing of SRRM4 promote microexon inclusion?", "documents": [], "snippets": []}, {"id": "63f03a20f36125a42600001c", "type": "list", "body": "Which drugs are included in the AZD7442?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33532768", "http://www.ncbi.nlm.nih.gov/pubmed/35993765", "http://www.ncbi.nlm.nih.gov/pubmed/35871089", "http://www.ncbi.nlm.nih.gov/pubmed/35904210", "http://www.ncbi.nlm.nih.gov/pubmed/36443846", "http://www.ncbi.nlm.nih.gov/pubmed/35914259", "http://www.ncbi.nlm.nih.gov/pubmed/36411267", "http://www.ncbi.nlm.nih.gov/pubmed/35443106", "http://www.ncbi.nlm.nih.gov/pubmed/35076282"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/36443846", "text": "entric study to evaluate pre-exposure prophylaxis with AZD7442 (tixagevimab/cilgavimab) for preventing COVID-19 in adult allogeneic hematopoietic stem", "offsetInBeginSection": 251, "offsetInEndSection": 401, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35993765", "text": " against anti-SARS-CoV-2 monoclonal antibodies (MAbs) tixagevimab and cilgavimab, the components of AZD7442, prior to in vitro pseudovirus neutralizat", "offsetInBeginSection": 2184, "offsetInEndSection": 2334, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35443106", "text": "ND\nThe monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory", "offsetInBeginSection": 8, "offsetInEndSection": 158, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35914259", "text": "evin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N Engl J Med. 2022;386:2188-200. 3", "offsetInBeginSection": 1, "offsetInEndSection": 151, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35993765", "text": "variants against anti-SARS-CoV-2 monoclonal antibodies (MAbs) tixagevimab and cilgavimab, the components of AZD7442, prior to in vitro pseudovirus neu", "offsetInBeginSection": 2176, "offsetInEndSection": 2326, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36411267", "text": "GROUND\nWe report primary results of a phase 3 trial of AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis to prevent symptomatic coronavir", "offsetInBeginSection": 4, "offsetInEndSection": 154, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35904210", "text": "BACKGROUND\nIntramuscular AZD7442 (Tixagevimab-Cilgavimab, (Evusheld)) has been found effective among immunocompromised individuals (ICI) in reducing S", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35871089", "text": "d change reduction\u2009~\u20092.7). Within the Evusheld /AZD7442 cocktail, Cilgavimab/AZD1061 is more active against BA.2 and BA.5 than against BA.1 (fold chan", "offsetInBeginSection": 681, "offsetInEndSection": 831, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33532768", "text": "e determined the structures of two human monoclonal antibodies COV2-2196 and COV2-21301, which form the basis of the investigational antibody cocktail", "offsetInBeginSection": 236, "offsetInEndSection": 386, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35076282", "text": "ere, we describe AZD7442, a combination of two mAbs, AZD8895 (tixagevimab) and AZD1061 (cilgavimab), that simultaneously bind to distinct, nonoverlapp", "offsetInBeginSection": 392, "offsetInEndSection": 542, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640ddd9d201352f04a000028", "type": "list", "body": "What were the first 2 PD-1 inhibitors approved by the FDA in 2014?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30304963", "http://www.ncbi.nlm.nih.gov/pubmed/27058852", "http://www.ncbi.nlm.nih.gov/pubmed/28546286", "http://www.ncbi.nlm.nih.gov/pubmed/26285788", "http://www.ncbi.nlm.nih.gov/pubmed/29357948", "http://www.ncbi.nlm.nih.gov/pubmed/34196068"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29357948", "text": "s paved way for the development of the first PD-1 inhibitors, nivolumab and pembrolizumab, approved by the Food and Drug Administration (FDA) in 2014.", "offsetInBeginSection": 447, "offsetInEndSection": 597, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27058852", "text": "and Drug Administration (FDA) has approved 2 PD-1 inhibitors, nivolumab and pembrolizumab, and several others are under investigation. Although PD-1 i", "offsetInBeginSection": 543, "offsetInEndSection": 693, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26285788", "text": "tration (FDA) was canagliflozin in March 2013. Two agents - dapagliflozin and empagliflozin - were FDA-approved in January and July 2014, respectively", "offsetInBeginSection": 599, "offsetInEndSection": 749, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30304963", "text": "FDA) approved the first PD-1 targeting agent, namely pembrolizumab, shortly followed by nivolumab. Areas covered: Nivolumab is a fully human immunoglo", "offsetInBeginSection": 360, "offsetInEndSection": 510, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34196068", "text": "od and Drug Administration (FDA) approvals of programmed death (PD)-1 and PD-ligand 1 blocking antibodies (collectively referred to as PD-[L]1 inhibit", "offsetInBeginSection": 46, "offsetInEndSection": 196, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28546286", "text": " inhibitor, pembrolizumab, and two PD-L1 checkpoint inhibitors, avelumab and durvalumab, to treat metastatic urothelial carcinoma in patients whose di", "offsetInBeginSection": 40, "offsetInEndSection": 190, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414c4cf690f196b51000006", "type": "factoid", "body": "What is the difference between dermatillomania and skin picking disorder?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29298167", "http://www.ncbi.nlm.nih.gov/pubmed/31777356", "http://www.ncbi.nlm.nih.gov/pubmed/32106136", "http://www.ncbi.nlm.nih.gov/pubmed/32541332", "http://www.ncbi.nlm.nih.gov/pubmed/33654612", "http://www.ncbi.nlm.nih.gov/pubmed/28761349"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/32106136", "text": "Disorders, Fifth Edition and characterized by repetitive skin picking behaviors resulting in skin lesions. Atomoxetine (ATX) is a selective norepineph", "offsetInBeginSection": 209, "offsetInEndSection": 359, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31777356", "text": "aphic measurement is a consistent way of assessing skin lesions, but it does not reflect the impact of skin picking disorder on the individual's life.", "offsetInBeginSection": 1690, "offsetInEndSection": 1840, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33654612", "text": "illomania is a condition that leads to repetitive\u00a0picking of their skin ending up in skin and soft tissue damage. It is classified in\u00a0Diagnostic and S", "offsetInBeginSection": 41, "offsetInEndSection": 191, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28761349", "text": "omania), is described as recurrent picking of skin, leading to skin lesions and significant distress or functional impairment. ED is listed as one of ", "offsetInBeginSection": 467, "offsetInEndSection": 617, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29298167", "text": " picking sufficient to damage cutaneous tissue, but with no underlying dermatological disease. The condition appears as an independent diagnosis in th", "offsetInBeginSection": 63, "offsetInEndSection": 213, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32541332", "text": "tal Disorders, Fifth Edition, and characterized by unintentional, repetitive skin picking behaviors. Atomoxetine is a selective noradrenaline reuptake", "offsetInBeginSection": 233, "offsetInEndSection": 383, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eefa3bf36125a426000012", "type": "factoid", "body": "What causes Japanese Spotted Fever?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27197438", "http://www.ncbi.nlm.nih.gov/pubmed/23743544", "http://www.ncbi.nlm.nih.gov/pubmed/31186196", "http://www.ncbi.nlm.nih.gov/pubmed/9204291", "http://www.ncbi.nlm.nih.gov/pubmed/29968555", "http://www.ncbi.nlm.nih.gov/pubmed/35545515", "http://www.ncbi.nlm.nih.gov/pubmed/1431380", "http://www.ncbi.nlm.nih.gov/pubmed/33510192", "http://www.ncbi.nlm.nih.gov/pubmed/18411764", "http://www.ncbi.nlm.nih.gov/pubmed/31645532"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33510192", "text": "Japanese spotted fever, a tick-borne disease caused by Rickettsia japonica, was firstly described in southwestern Japan. There was a suspicion of Rick", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31645532", "text": "r (JSF) is an uncommon but potentially fatal infection transmitted by tick bites. We herein report a fulminant case of JSF infection that occurred in ", "offsetInBeginSection": 21, "offsetInEndSection": 171, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31186196", "text": "ory concentrations (MICs) of several antibacterial agents against Rickettsia japonica, which causes Japanese spotted fever. A plaque reduction assay a", "offsetInBeginSection": 56, "offsetInEndSection": 206, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27197438", "text": "rein on a case of severe Japanese spotted fever complicated by acute respiratory failure in Kobe City. A 70-year-old female presenting with general ma", "offsetInBeginSection": 12, "offsetInEndSection": 162, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23743544", "text": "anese spotted fever, who is the youngest reported patient so far. Tick-borne diseases, including Japanese spotted fever, should be included in the dif", "offsetInBeginSection": 58, "offsetInEndSection": 208, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9204291", "text": "Spotted fever group (SFG) rickettsioses, which are transmitted by ticks, were long thought not to exist in Japan. Three clinical cases of Japanese spo", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29968555", "text": "se spotted fever (JSF) is a zoonosis transmitted by ticks carrying the pathogen Rickettsia japonica. The classic triad of JSF symptoms is high fever, ", "offsetInBeginSection": 6, "offsetInEndSection": 156, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35545515", "text": "JSF is considered an occupational disease. It is frequently caused by tick bites while working in the mountain areas of citrus cultivations. Hence, ci", "offsetInBeginSection": 1944, "offsetInEndSection": 2094, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18411764", "text": " Japanese spotted fever is generaly a curative disease with early diagnosis and minocycline. In this case, the patient died 3 days after proper diagno", "offsetInBeginSection": 980, "offsetInEndSection": 1130, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1431380", "text": "in skin inspection, so that it was clinically speculated to be caused by ticks. According to out field research, the tick fauna was very rich througho", "offsetInBeginSection": 211, "offsetInEndSection": 361, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640dde93201352f04a000029", "type": "summary", "body": "What is the difference between PD-1 and PD-L1?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34271938", "http://www.ncbi.nlm.nih.gov/pubmed/31190978", "http://www.ncbi.nlm.nih.gov/pubmed/26552662", "http://www.ncbi.nlm.nih.gov/pubmed/33380881", "http://www.ncbi.nlm.nih.gov/pubmed/34077347", "http://www.ncbi.nlm.nih.gov/pubmed/27531770", "http://www.ncbi.nlm.nih.gov/pubmed/26239088", "http://www.ncbi.nlm.nih.gov/pubmed/31237152", "http://www.ncbi.nlm.nih.gov/pubmed/29545941"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26552662", "text": "(21.6-37.6%) and 13.5% (10.6-16.3%), respectively. The difference was significant (Z = 4.39, p < 0.001). The PFSR6m for PD-L1 positive and negative NS", "offsetInBeginSection": 1007, "offsetInEndSection": 1157, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33380881", "text": "ficity was lower. Further, we found that there is no statistically significant difference in efficacy between PD-1 and PD-L1 drugs.\n\n\nConclusions\nUrot", "offsetInBeginSection": 1380, "offsetInEndSection": 1530, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29545941", "text": "eutic options for several tumor types. Nonetheless, the differences in efficacy between PD-1/PD-L1 inhibitors and conventional treatments (chemotherap", "offsetInBeginSection": 136, "offsetInEndSection": 286, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27531770", "text": "that of PD-L1(-) patients, the difference between 2 groups was statistically significant (P<0.05); the expression rate of PD-L1(+) in patients with AL", "offsetInBeginSection": 1209, "offsetInEndSection": 1359, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26552662", "text": "were 66.8% (44.8%-88.9%) and 54.0% (32.6-75.3%). The difference was not significant (Z = 0.77, p = 0.441). Anti-PD-1/PD-L1 antibody can serve as a pro", "offsetInBeginSection": 1311, "offsetInEndSection": 1461, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26239088", "text": "nt cells. The programmed cell death 1 (PD-1)/PD-L1 pathway inhibits host antitumor responses; however, little is known about how this pathway function", "offsetInBeginSection": 153, "offsetInEndSection": 303, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31190978", "text": "IN and EGC compared with LGIN, and both PD-1 and PD-L1 showed similar expression patterns, being mainly detected in infiltrating immune cells. FACS al", "offsetInBeginSection": 1067, "offsetInEndSection": 1217, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34077347", "text": ") metastases.\n\n\nOBJECTIVE\nThis study aimed to assess the difference in efficacy of PD-1 or PD-L1 inhibitors in patients with and without CNS metastase", "offsetInBeginSection": 185, "offsetInEndSection": 335, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34271938", "text": " in cancer cases compared with benign tissues, whereas no difference in PD-1 positive expression was found. Moreover, the PD-L1 expression in tumour c", "offsetInBeginSection": 721, "offsetInEndSection": 871, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31237152", "text": "ive patients, the subgroup difference remains only in terms of progression-free survival. Conclusion: This meta-analysis confirms the superiority of I", "offsetInBeginSection": 667, "offsetInEndSection": 817, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410f8b2201352f04a000033", "type": "summary", "body": "What would be the benefits of using a virtual digital twin in nutrition?", "documents": [], "snippets": []}, {"id": "64040af9201352f04a00000d", "type": "yesno", "body": "Is levosimendan effective for amyotrophic lateral sclerosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35278658", "http://www.ncbi.nlm.nih.gov/pubmed/17685869", "http://www.ncbi.nlm.nih.gov/pubmed/32714567", "http://www.ncbi.nlm.nih.gov/pubmed/22206942", "http://www.ncbi.nlm.nih.gov/pubmed/31315908", "http://www.ncbi.nlm.nih.gov/pubmed/34901853", "http://www.ncbi.nlm.nih.gov/pubmed/22047468", "http://www.ncbi.nlm.nih.gov/pubmed/30530996", "http://www.ncbi.nlm.nih.gov/pubmed/34376973", "http://www.ncbi.nlm.nih.gov/pubmed/32639325"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22047468", "text": "dly progressive, fatal neurodegenerative disorder for which there is no effective treatment. The diagnosis is dependent on the clinical presentation a", "offsetInBeginSection": 52, "offsetInEndSection": 202, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30530996", "text": "st common neurodegenerative disease affecting motor neurons, lacks an effective treatment. A small fraction of amyotrophic lateral sclerosis cases hav", "offsetInBeginSection": 37, "offsetInEndSection": 187, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34901853", "text": "rative disease. Despite decades of clinical trials, effective disease-modifying drugs remain scarce. To understand the challenges of trial design and ", "offsetInBeginSection": 74, "offsetInEndSection": 224, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31315908", "text": "OBJECTIVE\nTo evaluate the efficacy and safety of oral levosimendan in patients with amyotrophic lateral sclerosis (ALS). This phase II, randomised, do", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17685869", "text": "ation of motor neurons in the brain and spinal cord. There are still no other effective therapies 10 years after the approval of riluzole for the trea", "offsetInBeginSection": 60, "offsetInEndSection": 210, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32639325", "text": "range of cardiac and noncardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral scler", "offsetInBeginSection": 1012, "offsetInEndSection": 1162, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34376973", "text": "ac settings (eg, septic shock, pulmonary hypertension) and for non-cardiac applications (eg, amyotrophic lateral sclerosis). This narrative review out", "offsetInBeginSection": 619, "offsetInEndSection": 769, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32714567", "text": "ange of cardiac and non-cardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral scler", "offsetInBeginSection": 1009, "offsetInEndSection": 1159, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35278658", "text": "cations, such as injuries to the liver and kidney. To date, there is no effective treatment for amyotrophic lateral sclerosis. In this regard, investi", "offsetInBeginSection": 285, "offsetInEndSection": 435, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22206942", "text": "There is currently very limited effective pharmacological treatment for amyotrophic lateral sclerosis. Recent evidence suggests that caffeic acid phen", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414c0f7690f196b51000001", "type": "list", "body": "What are the clinical symptoms of an ornithine transcarbamylase deficiency?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17209350", "http://www.ncbi.nlm.nih.gov/pubmed/30671162", "http://www.ncbi.nlm.nih.gov/pubmed/10799432", "http://www.ncbi.nlm.nih.gov/pubmed/10910641", "http://www.ncbi.nlm.nih.gov/pubmed/8040774", "http://www.ncbi.nlm.nih.gov/pubmed/25011434", "http://www.ncbi.nlm.nih.gov/pubmed/25687292", "http://www.ncbi.nlm.nih.gov/pubmed/22138526", "http://www.ncbi.nlm.nih.gov/pubmed/7155674"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25011434", "text": "manifestations of ornithine transcarbamylase deficiency included vomiting and seizure, which were the most frequent signs at admission. Two of the fou", "offsetInBeginSection": 859, "offsetInEndSection": 1009, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8040774", "text": "Recurrent episodes of bizarre behavior were the only clinical symptoms that finally led to the diagnosis of ornithine transcarbamylase deficiency in a", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17209350", "text": "d urea cycle disorder. Its clinical manifestations as lethargy, vomites, coma and cerebral edema are the effect of the higher concentration of the amm", "offsetInBeginSection": 65, "offsetInEndSection": 215, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10799432", "text": "e transcarbamylase deficiency emphasises the need for plasma ammonia and amino acid measurements in clinical situations suggesting a disorder of this ", "offsetInBeginSection": 181, "offsetInEndSection": 331, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10910641", "text": " dominant trait. Clinical manifestations are more severe in hemizygous males than in heterozygous females. To date about 160 different mutations and 1", "offsetInBeginSection": 128, "offsetInEndSection": 278, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22138526", "text": "ency gene. In pregnancy it has been associated with altered mental status, seizures, coma and death, especially in the postpartum period. We report th", "offsetInBeginSection": 157, "offsetInEndSection": 307, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25687292", "text": "s are mostly due to hyperammonemia and include nausea, vomiting, lethargia and even convulsions and coma. Common neurological symptoms at presentation", "offsetInBeginSection": 264, "offsetInEndSection": 414, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7155674", "text": "ee for 9 months and then developed an acute episode with liver failure and metabolic imbalance. Subsequently there was severe cerebral atrophy. Liver ", "offsetInBeginSection": 80, "offsetInEndSection": 230, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30671162", "text": "ts in the neonatal period. Late-onset presentation of OTC can cause mild to severe symptoms. We describe laboratory and clinical findings of late-onse", "offsetInBeginSection": 97, "offsetInEndSection": 247, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30671162", "text": "and severity in late-onset presentation of OTC ranging from seizures to cerebral herniation. Our literature review is the first to detail published la", "offsetInBeginSection": 1133, "offsetInEndSection": 1283, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63fa197c201352f04a000003", "type": "summary", "body": "How does SRSF11 contribute to metastasis potential of colorectal cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36394206"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/36394206", "text": "protein family, the involvement of SRSF11 in colorectal cancer (CRC) is unknown.\n\n\nMETHODS\nThe TCGA dataset and clinical samples were used to assess S", "offsetInBeginSection": 195, "offsetInEndSection": 345, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eef60ef36125a42600000c", "type": "factoid", "body": "Olokizumab is tested for which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24670876", "http://www.ncbi.nlm.nih.gov/pubmed/36001712", "http://www.ncbi.nlm.nih.gov/pubmed/24641941", "http://www.ncbi.nlm.nih.gov/pubmed/33720587", "http://www.ncbi.nlm.nih.gov/pubmed/34101570"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34101570", "text": "an anti-interleukin (IL)-6 monoclonal antibody, in patients with rheumatoid arthritis (RA) and inadequate response to tumor necrosis factor-alpha inhi", "offsetInBeginSection": 94, "offsetInEndSection": 244, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24641941", "text": "OKZ), a humanised anti-IL6 monoclonal antibody, in patients with rheumatoid arthritis (RA) with moderate-to-severe disease activity who had previously", "offsetInBeginSection": 104, "offsetInEndSection": 254, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36001712", "text": "leukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis.\n\n\nMETHODS\nIn a 24-week, phase 3, multicenter, placebo- and acti", "offsetInBeginSection": 158, "offsetInEndSection": 308, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34101570", "text": "expected for IL-6 blocking agents without new safety signals and led to sustained improvements in RA symptoms, physical function, and quality of life.", "offsetInBeginSection": 1916, "offsetInEndSection": 2066, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24670876", "text": "ical regulator of the immune system and has been widely implicated in autoimmune disease. Here, we describe the discovery and characterization of olok", "offsetInBeginSection": 30, "offsetInEndSection": 180, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36001712", "text": "those receiving it every 4 weeks.\n\n\nCONCLUSIONS\nIn patients with rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was supe", "offsetInBeginSection": 2359, "offsetInEndSection": 2509, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33720587", "text": "izumab) for the treatment of subjects with a disease caused by the SARS-COV-2 virus in a real-world clinical setting.\n\n\nMATERIALS AND METHODS\nThe anal", "offsetInBeginSection": 442, "offsetInEndSection": 592, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33720587", "text": "observation.\n\n\nCONCLUSION\nThe use of olokizumab to treat the new COVID-19 coronavirus disease has demonstrated a positive effect on clinical and labor", "offsetInBeginSection": 1489, "offsetInEndSection": 1639, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33720587", "text": "rch and observation.\n\n\nCONCLUSION\nThe use of olokizumab to treat the new COVID-19 coronavirus disease has demonstrated a positive effect on clinical a", "offsetInBeginSection": 1481, "offsetInEndSection": 1631, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36001712", "text": "other domains) at week 12, with each olokizumab dose tested for superiority to placebo. We also tested the noninferiority of each olokizumab dose to a", "offsetInBeginSection": 772, "offsetInEndSection": 922, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6413730e201352f04a00003f", "type": "summary", "body": "Please summarize the function of Trophinin-associated protein (TROAP)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30431120", "http://www.ncbi.nlm.nih.gov/pubmed/35708862", "http://www.ncbi.nlm.nih.gov/pubmed/29117881", "http://www.ncbi.nlm.nih.gov/pubmed/30021381", "http://www.ncbi.nlm.nih.gov/pubmed/33500384", "http://www.ncbi.nlm.nih.gov/pubmed/33692939", "http://www.ncbi.nlm.nih.gov/pubmed/30854102", "http://www.ncbi.nlm.nih.gov/pubmed/31285897", "http://www.ncbi.nlm.nih.gov/pubmed/18554632"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18554632", "text": "TS\nThe presence of trophinin and the trophinin associated proteins bystin and tastin in human sperm was confirmed by immunohistochemistry. Human sperm", "offsetInBeginSection": 1175, "offsetInEndSection": 1325, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35708862", "text": "BACKGROUND\nTrophinin-associated protein (TROAP) mediates embryonic transfer, regulates microtubules, and is associated with the biological behavior of", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33692939", "text": "sociated protein (TROAP) has been shown to be overexpressed and promotes tumor progression in some tumors. We performed this study to assess the biolo", "offsetInBeginSection": 12, "offsetInEndSection": 162, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33500384", "text": "ctopic expression of trophinin-associated protein (TROAP) dramatically drove HCC cell growth assessed by foci formation in monolayer culture, colony f", "offsetInBeginSection": 132, "offsetInEndSection": 282, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29117881", "text": ". Taken together, these results indicate that TROAP suppresses cellular growth and migration in HCC. This discovery will further our understanding of ", "offsetInBeginSection": 1099, "offsetInEndSection": 1249, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31285897", "text": " (TROAP) is a cytoplasmic protein first identified to mediate the process of embryo transplantation, which has been recently found to be involved in m", "offsetInBeginSection": 177, "offsetInEndSection": 327, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30854102", "text": " that plays a significant role in the processes of embryo transplantation and microtubule regulation. However, the relevant survival analysis and canc", "offsetInBeginSection": 70, "offsetInEndSection": 220, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30431120", "text": "s essential for centrosome integrity and proper bipolar organisation of spindle assembly during mitosis and plays an essential role in proliferation. ", "offsetInBeginSection": 180, "offsetInEndSection": 330, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18554632", "text": "essed in human sperm, to our knowledge the function of this protein is not known. In this study we tested the effect of GWRQ on human sperm to evaluat", "offsetInBeginSection": 179, "offsetInEndSection": 329, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30021381", "text": "erified that trophinin associated protein (TROAP) was a direct target of miR-519d-3p in CRC cells. Using Oncomine database analysis, TROAP was confirm", "offsetInBeginSection": 1183, "offsetInEndSection": 1333, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410ed73201352f04a00002f", "type": "summary", "body": "How does SRSF11 promote metastasis of colon cancer?", "documents": [], "snippets": []}, {"id": "63f03fc8f36125a426000021", "type": "factoid", "body": "What disease can be treated with Lenacapavir?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36411257", "http://www.ncbi.nlm.nih.gov/pubmed/36272024", "http://www.ncbi.nlm.nih.gov/pubmed/34871187", "http://www.ncbi.nlm.nih.gov/pubmed/35544387", "http://www.ncbi.nlm.nih.gov/pubmed/35028668"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34871187", "text": "ng studies are evaluating long-acting dosing of lenacapavir for treating HIV-1 in combination with other antiretrovirals and preventing HIV-1 as a sin", "offsetInBeginSection": 858, "offsetInEndSection": 1008, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35028668", "text": " conducted in a Phase 1b study of lenacapavir (Study 4072) in people with HIV (PWH).\n\n\nMETHODS\nMutations were inserted in a proviral DNA clone by site", "offsetInBeginSection": 308, "offsetInEndSection": 458, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35028668", "text": "bo-controlled, dose-ranging, randomized study of lenacapavir in untreated PWH. Participants received a single dose of lenacapavir (up to 750 mg) or pl", "offsetInBeginSection": 794, "offsetInEndSection": 944, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35544387", "text": " substitutions).\n\n\nCONCLUSIONS\nIn patients with multidrug-resistant HIV-1 infection, those who received lenacapavir had a greater reduction from basel", "offsetInBeginSection": 2216, "offsetInEndSection": 2366, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36411257", "text": " its predicted effectiveness for treatment and prevention, regardless of HIV-1 clades. The established conserved regions hence serve as a hallmark for", "offsetInBeginSection": 1256, "offsetInEndSection": 1406, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36272024", "text": "regimen. This article summarizes the milestones in the development of lenacapavir leading to this first approval for the treatment of HIV-1 infection.", "offsetInBeginSection": 546, "offsetInEndSection": 696, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34871187", "text": "ing antiretroviral classes and potent antiviral activity in persons with HIV-1. In persons with HIV-1, there was no preexisting resistance to lenacapa", "offsetInBeginSection": 311, "offsetInEndSection": 461, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35544387", "text": "BACKGROUND\nPatients with multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection have limited treatment options. Lenacapavir is a fi", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "641365f6201352f04a00003a", "type": "yesno", "body": "Is Iron deficiency anemia a common complication of chronic kidney disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17804903", "http://www.ncbi.nlm.nih.gov/pubmed/16470356", "http://www.ncbi.nlm.nih.gov/pubmed/22303745", "http://www.ncbi.nlm.nih.gov/pubmed/30970355", "http://www.ncbi.nlm.nih.gov/pubmed/17533016", "http://www.ncbi.nlm.nih.gov/pubmed/29696955"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/17804903", "text": "Iron deficiency anemia is common in people with chronic kidney disease (CKD) and its importance in supporting erythropoiesis is unquestioned especiall", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17533016", "text": "he nondialysis chronic kidney disease population. Limited data suggest that iron deficiency is common in patients with chronic kidney disease with ane", "offsetInBeginSection": 160, "offsetInEndSection": 310, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30970355", "text": "Iron deficiency anemia is a common complication of chronic kidney disease (CKD). CKD patients suffer from both absolute and functional iron deficiency", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22303745", "text": " diabetic nephropathy is a leading cause of CKD. One of the most common complications of CKD is anemia, the frequency and severity of which increase a", "offsetInBeginSection": 58, "offsetInEndSection": 208, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16470356", "text": "Anemia is as a frequent complication in patients with chronic kidney disease, which gains in importance in the treatment of patients with renal diseas", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29696955", "text": "Anemia is the most common disorder\nof the blood with iron deficiency\nbeing the predominant cause. On the\nother hand, diabetes prevalence is\nincreasing", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410ef9b201352f04a000031", "type": "yesno", "body": "Can modulation of KCNQ1 splicing prevent arrhythmias?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23608591"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23608591", "text": "nd reduces arrhythmogenicity through the modulation of KCNQ1 splicing. We suggested that the modulation of KCNQ1 splicing may help prevent arrhythmia.", "offsetInBeginSection": 1615, "offsetInEndSection": 1765, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23608591", "text": "ial duration (APD) in cardiac myocytes. The consequences of drug-induced KCNQ1 splice alteration remain unknown.\n\n\nOBJECTIVE\nTo study the modulation o", "offsetInBeginSection": 173, "offsetInEndSection": 323, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f57f7f33942b094c000006", "type": "summary", "body": "What is Catamenial pneumothorax?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27516783", "http://www.ncbi.nlm.nih.gov/pubmed/11715807", "http://www.ncbi.nlm.nih.gov/pubmed/15887438", "http://www.ncbi.nlm.nih.gov/pubmed/17540999", "http://www.ncbi.nlm.nih.gov/pubmed/19670769", "http://www.ncbi.nlm.nih.gov/pubmed/12097775", "http://www.ncbi.nlm.nih.gov/pubmed/19033519", "http://www.ncbi.nlm.nih.gov/pubmed/16113003", "http://www.ncbi.nlm.nih.gov/pubmed/28925275"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28925275", "text": "AIM\nCatamenial pneumothorax is menstrual cycle dependent and represents the most common form of thoracic endometriosis syndrome. Recurrences are very ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11715807", "text": " catamenial pneumothorax. Catamenial pneumothorax is one of the forms of spontaneous pneumothorax. An integral part of the paper is a review of the li", "offsetInBeginSection": 78, "offsetInEndSection": 228, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15887438", "text": "ial pneumothorax is defined as spontaneous pneumothorax occurring within 72 hours before or after onset of menstruation. Although catamenial pneumotho", "offsetInBeginSection": 7, "offsetInEndSection": 157, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16113003", "text": "Catamenial pneumothorax, a variant of spontaneous pneumothorax occurs exclusively in women of menstrual age. Catamenial pneumothorax is associated wit", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19670769", "text": "illness every month. Since catamenial pneumothorax is caused by thoracic endometriosis, decisions on treatment should be made with a gynecologist's op", "offsetInBeginSection": 1070, "offsetInEndSection": 1220, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19033519", "text": " the Greek meaning \"monthly\". Catamenial pneumothorax is a rare complication of endometriosis. A patient with a history of endometriosis presented to ", "offsetInBeginSection": 229, "offsetInEndSection": 379, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19670769", "text": "Catamenial pneumothorax is an rare disease which arise in women during menses, etiologically related to endometriosis of diaphragm and lung. The five ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27516783", "text": "d be defined as recurrent accumulation of air in the pleural cavity in reproductive-age women without concomitant respiratory diseases. The sine qua n", "offsetInBeginSection": 29, "offsetInEndSection": 179, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12097775", "text": "Catamenial pneumothorax is a rarely encountered entity characterized by recurrent pneumothorax concurrent with menstruation. Numerous mechanisms have ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17540999", "text": "Catamenial pneumothorax is a recurrent pneumothorax temporally associated with menstruation. Pathogenesis remains debated however pleural endometriosi", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64144419201352f04a000045", "type": "summary", "body": "Please summarize haptenization.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15237856"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/15237856", "text": "he innate immune system, or haptenization eliciting an immunoallergic response of the adaptive immune system. Besides licensed drugs, herbal and natur", "offsetInBeginSection": 813, "offsetInEndSection": 963, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414c124690f196b51000002", "type": "yesno", "body": "Is trichotillomania encountered with equali frequency in males and females?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11286115", "http://www.ncbi.nlm.nih.gov/pubmed/10216392", "http://www.ncbi.nlm.nih.gov/pubmed/29753253", "http://www.ncbi.nlm.nih.gov/pubmed/19479123", "http://www.ncbi.nlm.nih.gov/pubmed/9332906", "http://www.ncbi.nlm.nih.gov/pubmed/30440191", "http://www.ncbi.nlm.nih.gov/pubmed/23116460", "http://www.ncbi.nlm.nih.gov/pubmed/30901067", "http://www.ncbi.nlm.nih.gov/pubmed/18970906"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23116460", "text": "1%). Among these students, 19 (9.0%) were engaged in dermatillomania, 28 (13.3%) in trichotillomania and 13 (6.2%) in onychophagia.\n\n\nCONCLUSIONS\nHigh", "offsetInBeginSection": 1149, "offsetInEndSection": 1299, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10216392", "text": "a, substance abuse, borderline personality, obsessive-compulsive disorder. Its onset is usually in childhood and females are more affected than males.", "offsetInBeginSection": 277, "offsetInEndSection": 427, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18970906", "text": "tatistical Manual of Mental Disorders, Fourth Edition, trichotillomania (85.3% females; mean age, 35.0 +/- 12.5). Comorbidity data were obtained with ", "offsetInBeginSection": 297, "offsetInEndSection": 447, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30901067", "text": "ified as an obsessive-compulsive spectrum disorder and is seen predominantly in females. This is a non-systematic review article focusing on the psych", "offsetInBeginSection": 52, "offsetInEndSection": 202, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29753253", "text": "Trichotillomania is several times more common in women and has peak onset around puberty. The role of sex hormones, however, has received little resea", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19479123", "text": "gh trichotillomania is a relatively common disorder no large epidemiological studies are available. The aims of this study were to determine the frequ", "offsetInBeginSection": 6, "offsetInEndSection": 156, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18970906", "text": " .010).\n\n\nCONCLUSIONS\nThese preliminary results suggest that trichophagia is not uncommon in individuals with trichophagia. Subjects with and without ", "offsetInBeginSection": 1397, "offsetInEndSection": 1547, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11286115", "text": "ubsequent sense of relief. The mean age of onset is 8 years for males and 12 for females. Hair is pulled from a variety of sites, most frequently from", "offsetInBeginSection": 392, "offsetInEndSection": 542, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9332906", "text": ", and it may be effective in a subset of patients. Given the relatively low response rate, however, a controlled trial is needed before this agent can", "offsetInBeginSection": 887, "offsetInEndSection": 1037, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30440191", "text": "Trichotillomania is a relatively uncommon condition that classically occurs in young females. It can result in trichobezoar formation, which is usuall", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64041701201352f04a000017", "type": "list", "body": "What is the triad of the Eagle-Barrett Syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30560020", "http://www.ncbi.nlm.nih.gov/pubmed/24833922", "http://www.ncbi.nlm.nih.gov/pubmed/35429431", "http://www.ncbi.nlm.nih.gov/pubmed/6231520", "http://www.ncbi.nlm.nih.gov/pubmed/12579407", "http://www.ncbi.nlm.nih.gov/pubmed/142096"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35429431", "text": "cterized by the triad of absent or defective abdominal wall muscles, urinary tract abnormalities, and bilateral cryptorchidism. Ureteropelvic junction", "offsetInBeginSection": 65, "offsetInEndSection": 215, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12579407", "text": "BS) is characterized by the triad of abdominal muscle deficiency, urinary tract abnormalities, and cryptorchidism. Approximately 25% of patients with ", "offsetInBeginSection": 25, "offsetInEndSection": 175, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30560020", "text": "owing triad of symptoms: deficiency of the abdominal muscles, malformations of the urinary tract, and bilateral cryptorchidism. The exact etiology is ", "offsetInBeginSection": 160, "offsetInEndSection": 310, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/142096", "text": "dder in a 20 1/2 week fetus which subsequently was proven to have the prune belly or Eagle-Barrett syndrome. Serial sonograms were used to follow the ", "offsetInBeginSection": 76, "offsetInEndSection": 226, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6231520", "text": "malities, and cryptorchidism are the three major features of the prune-belly syndrome, also referred to as triad syndrome or Eagle-Barrett syndrome. T", "offsetInBeginSection": 48, "offsetInEndSection": 198, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24833922", "text": "The Female Athlete Triad (Triad) represents a syndrome of three interrelated conditions that originate from chronically inadequate energy intake to co", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640c85e9201352f04a000026", "type": "factoid", "body": "What cells proliferate in Mantle Cell Lymphoma", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11903572", "http://www.ncbi.nlm.nih.gov/pubmed/6362835", "http://www.ncbi.nlm.nih.gov/pubmed/22790016", "http://www.ncbi.nlm.nih.gov/pubmed/9753060"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/6362835", "text": "ocytic lymphoma which is characterized by a proliferation of atypical small lymphoid cells as wide mantles around benign-appearing germinal centers. I", "offsetInBeginSection": 86, "offsetInEndSection": 236, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9753060", "text": "features characterized by a monotonous proliferation of small-to-medium-sized irregular B cells that express CD5 and bright surface immunoglobulin IgM", "offsetInBeginSection": 181, "offsetInEndSection": 331, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11903572", "text": " RESULTS\nIn the initial manifestation in the palatine tonsils, the neoplastic cells were found to grow exclusively within the marginal zones of second", "offsetInBeginSection": 105, "offsetInEndSection": 255, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22790016", "text": "Recently, the occurrence of cyclin D1-positive B cells with mantle cell lymphoma phenotype in the inner mantle zones of morphologically inconspicuous ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6362835", "text": "lymphomas are derived from follicular center cells. Apparently, the lymphoid cells of MZL home to the mantle zones of secondary follicles, where they ", "offsetInBeginSection": 963, "offsetInEndSection": 1113, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415bb3c690f196b5100000e", "type": "factoid", "body": "What is the estimated cost reduction when using telegenetics?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20411313", "http://www.ncbi.nlm.nih.gov/pubmed/33027215", "http://www.ncbi.nlm.nih.gov/pubmed/26785833"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/20411313", "text": "legenetics. Telegenetics offered them convenience and reduced travel and associated costs. The majority of women described feeling a high degree of so", "offsetInBeginSection": 604, "offsetInEndSection": 754, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26785833", "text": "sfaction. One economic analysis published thus far reported lower costs than in-person care. We hypothesized that telegenetics can also be beneficial ", "offsetInBeginSection": 351, "offsetInEndSection": 501, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33027215", "text": "GS\nImplementation of telegenetics in health systems is still limited, below 10%, somewhat higher for cancer genetic counseling. Nevertheless, telegene", "offsetInBeginSection": 190, "offsetInEndSection": 340, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f03ae6f36125a42600001d", "type": "factoid", "body": "What is the target of BI 1015550?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35569036", "http://www.ncbi.nlm.nih.gov/pubmed/35517783", "http://www.ncbi.nlm.nih.gov/pubmed/36299369"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35569036", "text": "gent, prevented a decrease in lung function in patients with idiopathic pulmonary fibrosis. (Funded by Boehringer Ingelheim; 1305-0013 ClinicalTrials.", "offsetInBeginSection": 2035, "offsetInEndSection": 2185, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35569036", "text": "referential inhibitor of the PDE4B subtype, in patients with idiopathic pulmonary fibrosis. Patients were randomly assigned in a 2:1 ratio to receive ", "offsetInBeginSection": 312, "offsetInEndSection": 462, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35517783", "text": " antifibrotic potential, suggest BI 1015550 to be a promising oral clinical candidate for the treatment of IPF and other fibro-proliferative diseases.", "offsetInBeginSection": 2251, "offsetInEndSection": 2401, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35517783", "text": "antifibrotic potential of BI 1015550 in vivo, its direct effect on human fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) was invest", "offsetInBeginSection": 1443, "offsetInEndSection": 1593, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36299369", "text": "ics of BI 1015550 in healthy male subjects and patients with idiopathic pulmonary fibrosis (IPF).\n\n\nMethods\nIn the phase I study, 42 subjects were par", "offsetInBeginSection": 195, "offsetInEndSection": 345, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64089be7201352f04a000022", "type": "summary", "body": "Please summarize the difference between REMS and RMPs", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31122578"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/31122578", "text": "l severity of illness; however, no studies have adequately addressed the intra or inter-rater reliability of the score.\n\n\nCONCLUSIONS\nThere is evidenc", "offsetInBeginSection": 1085, "offsetInEndSection": 1235, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f9cd2f33942b094c000011", "type": "yesno", "body": "Does microexon alternative splicing of small GTPase regulators have implication in central nervous system diseases?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35841978", "http://www.ncbi.nlm.nih.gov/pubmed/30404949"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35841978", "text": "r, its implication in cardiovascular embryogenesis and diseases remains largely unknown. In this review, we summarize previous findings and reveal the", "offsetInBeginSection": 416, "offsetInEndSection": 566, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30404949", "text": "ing events. However, the functional significance of microexons and their contribution to signaling diversity is poorly understood. The Met receptor ty", "offsetInBeginSection": 105, "offsetInEndSection": 255, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eeeaaaf36125a426000004", "type": "factoid", "body": "Beremagene Geperpavec is tested for which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35347281"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35347281", "text": "COL7A1 containing herpes simplex virus type 1 (HSV-1) vector, to treat RDEB skin. B-VEC restored C7 expression in RDEB keratinocytes, fibroblasts, RDE", "offsetInBeginSection": 311, "offsetInEndSection": 461, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64138ce8201352f04a000042", "type": "factoid", "body": "Hairpatches is a single gene mutation associated with what disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23301070"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23301070", "text": "y alopecia. This mutation is a model for the rare human disorder \"glomerulonephritis with sparse hair and telangiectases\" (OMIM 137940). Fine mapping ", "offsetInBeginSection": 200, "offsetInEndSection": 350, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f9cd0b33942b094c000010", "type": "factoid", "body": "What is the alternative microexon splicing by RBFOX2 and PTBP1 associated with?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34731606"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34731606", "text": "h has a well-established role in alternative splicing, is linked to heart diseases. However, it is unclear whether RBFOX2 has other roles in RNA proce", "offsetInBeginSection": 12, "offsetInEndSection": 162, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f56f7533942b094c000002", "type": "factoid", "body": "Which gene is implicated in Canavan disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28626388", "http://www.ncbi.nlm.nih.gov/pubmed/18978679", "http://www.ncbi.nlm.nih.gov/pubmed/25177395", "http://www.ncbi.nlm.nih.gov/pubmed/17999961", "http://www.ncbi.nlm.nih.gov/pubmed/20129749", "http://www.ncbi.nlm.nih.gov/pubmed/17177147", "http://www.ncbi.nlm.nih.gov/pubmed/24682784", "http://www.ncbi.nlm.nih.gov/pubmed/8088831", "http://www.ncbi.nlm.nih.gov/pubmed/15907664", "http://www.ncbi.nlm.nih.gov/pubmed/24272958"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18978679", "text": "PURPOSE\nCanavan disease, caused by a deficiency of aspartoacylase, is one of the most common cerebral degenerative diseases of infancy. The aims of th", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17177147", "text": "s a childhood leukodystrophy caused by mutations in the gene for human aspartoacylase ( ASPA), which leads to an abnormal accumulation of the substrat", "offsetInBeginSection": 17, "offsetInEndSection": 167, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8088831", "text": "f the brain, is a severe leukodystrophy caused by the deficiency of aspartoacylase (ASPA). Recently, a missense mutation was identified in human ASPA ", "offsetInBeginSection": 41, "offsetInEndSection": 191, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17999961", "text": " over the world. Canavan disease is caused by a genetic mutation in aspartoacylase gene. We have identified a novel mutation, a homozygous C432+1G>A m", "offsetInBeginSection": 196, "offsetInEndSection": 346, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28626388", "text": "Canavan disease is caused by mutations in the gene encoding aspartoacylase (ASPA), a deacetylase that catabolizes N-acetylaspartate (NAA). The precise", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24272958", "text": "orm leukodystrophy caused by an autosomal recessive mutation in the aspartoacylase gene. Deficiency of oligodendroglial aspartoacylase activity and a ", "offsetInBeginSection": 28, "offsetInEndSection": 178, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15907664", "text": "Canavan disease (CD) is an autosomal recessive disorder caused by aspartoacylase (ASPA) gene mutations resulting enzyme deficiency. The homozygous kno", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24682784", "text": "Canavan disease is a leukodystrophy caused by mutations in the ASPA gene. This gene encodes the enzyme that converts N-acetylaspartate into acetate an", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25177395", "text": "00) is a rare autosomal recessive leukodystrophy due to mutations in the ASPA gene (MIM 608034) and characterized by a clinical onset at 3-5\u00a0months of", "offsetInBeginSection": 25, "offsetInEndSection": 175, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20129749", "text": "t two novel mutations: c.2T>C/M1T, an initiation codon mutation, and c.209A>G/N70S, which is located at the enzyme-substrate binding site. The combina", "offsetInBeginSection": 133, "offsetInEndSection": 283, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6411b4a8201352f04a000035", "type": "yesno", "body": "Is prosopagnosia also known as lack of auditory recognition?", "documents": [], "snippets": []}, {"id": "6415babe690f196b5100000d", "type": "summary", "body": "What is telegenetics?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25898928", "http://www.ncbi.nlm.nih.gov/pubmed/32132456", "http://www.ncbi.nlm.nih.gov/pubmed/26785833", "http://www.ncbi.nlm.nih.gov/pubmed/22498847", "http://www.ncbi.nlm.nih.gov/pubmed/35464100", "http://www.ncbi.nlm.nih.gov/pubmed/23393646", "http://www.ncbi.nlm.nih.gov/pubmed/20406122", "http://www.ncbi.nlm.nih.gov/pubmed/30559758", "http://www.ncbi.nlm.nih.gov/pubmed/34779303", "http://www.ncbi.nlm.nih.gov/pubmed/34265143"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34265143", "text": "isorders within the Department of Neurology were conducted via secure videoconferencing (telegenetics) or telephone between March and December 2020. A", "offsetInBeginSection": 241, "offsetInEndSection": 391, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23393646", "text": "re services. Telemedicine may also be effectively utilized in clinical genetics services\u2014an application that has been termed \u201ctelegenetics.\u201d\n\n\nMETHODS", "offsetInBeginSection": 164, "offsetInEndSection": 314, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22498847", "text": "re services. Telemedicine may also be effectively utilized in clinical genetics services-an application that has been termed \"telegenetics.\"\n\n\nMETHODS", "offsetInBeginSection": 164, "offsetInEndSection": 314, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25898928", "text": "atient-centered care delivery. Telegenetics could be an effective and efficient way of counseling, but its use in Europe is not widely reported, nor i", "offsetInBeginSection": 261, "offsetInEndSection": 411, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32132456", "text": "linic setting or in their homes. Telegenetics is a satisfactory solution for both patient and provider and provides benefits for rural patients despit", "offsetInBeginSection": 424, "offsetInEndSection": 574, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35464100", "text": "Telegenetics is the use of telemedicine to deliver clinical genetic services to patients. During the COVID-19 public health emergency (PHE), telegenet", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34779303", "text": "PURPOSE\nTelegenetics has become the predominant mode of cancer genetic counseling during the COVID-19 pandemic. We sought to identify potential patien", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20406122", "text": "OBJECTIVE\nVideoconferencing for clinical genetics services, or telegenetics, is becoming an increasingly utilized method of delivering genetic counsel", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26785833", "text": " and professionals. Most telegenetics reports describe applications in large geographical areas, showing positive patients' and professionals' satisfa", "offsetInBeginSection": 204, "offsetInEndSection": 354, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30559758", "text": "Telegenetics, the application of telemedicine in the context of genetic services, is a growing market. One of the recent developments in this field is", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f04546f36125a426000024", "type": "summary", "body": "What is the mechanism of action of Mitapivat?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35988546", "http://www.ncbi.nlm.nih.gov/pubmed/35366607", "http://www.ncbi.nlm.nih.gov/pubmed/36124781", "http://www.ncbi.nlm.nih.gov/pubmed/35576529", "http://www.ncbi.nlm.nih.gov/pubmed/35964609", "http://www.ncbi.nlm.nih.gov/pubmed/36260990", "http://www.ncbi.nlm.nih.gov/pubmed/31483964", "http://www.ncbi.nlm.nih.gov/pubmed/35417638"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35964609", "text": "cy of mitapivat (Agios Pharmaceuticals, Cambridge, MA, USA), a pyruvate kinase activator, in adults with non-transfusion-dependent (NTD) \u03b1-thalassaemi", "offsetInBeginSection": 303, "offsetInEndSection": 453, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36260990", "text": "agues1 evaluated the safety and efficacy of mitapivat, an oral pyruvate kinase activator, in\u00a0adults with non-transfusion-dependent \u03b1-thalassemia or \u03b2-", "offsetInBeginSection": 13, "offsetInEndSection": 163, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35576529", "text": "rved. This study provides proof of concept that mitapivat has disease-modifying potential in patients with SCD. This trial was registered at www.clini", "offsetInBeginSection": 1558, "offsetInEndSection": 1708, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35988546", "text": ") and 24-week fixed-dose period. The primary endpoint was a reduction in transfusion burden (\u226533% reduction in number of RBC units transfused during t", "offsetInBeginSection": 818, "offsetInEndSection": 968, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35366607", "text": "mitapivat yielded potential benefits in HbSS mice. Mitapivat further increased ATP without significantly changing 2,3-DPG or hemoglobin levels, and de", "offsetInBeginSection": 945, "offsetInEndSection": 1095, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35576529", "text": "thophysiology of sickle cell disease (SCD). In activating red blood cell pyruvate kinase and glycolysis, mitapivat (AG-348) increases adenosine tripho", "offsetInBeginSection": 60, "offsetInEndSection": 210, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35417638", "text": "l, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency.\n\n\nMETHODS\nIn t", "offsetInBeginSection": 158, "offsetInEndSection": 308, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35366607", "text": "y. These factors can be modulated by mitapivat, which activates erythrocyte pyruvate kinase (PKR) and improves sickling kinetics in SCD patients. We i", "offsetInBeginSection": 321, "offsetInEndSection": 471, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31483964", "text": "tic anemia. Mitapivat is an oral, small-molecule allosteric activator of pyruvate kinase in red cells.\n\n\nMETHODS\nIn this uncontrolled, phase 2 study, ", "offsetInBeginSection": 99, "offsetInEndSection": 249, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36124781", "text": "XPERT OPINION\nMitapivat is a first-in-class allosteric activator of pyruvate kinase and the first FDA-approved disease directed therapy for PKD. It ha", "offsetInBeginSection": 755, "offsetInEndSection": 905, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "641357bc201352f04a000039", "type": "yesno", "body": "Do cells undergoing necroptosis show disruption of their cell membranes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32156734", "http://www.ncbi.nlm.nih.gov/pubmed/27158445", "http://www.ncbi.nlm.nih.gov/pubmed/31138766", "http://www.ncbi.nlm.nih.gov/pubmed/35365636", "http://www.ncbi.nlm.nih.gov/pubmed/34539677", "http://www.ncbi.nlm.nih.gov/pubmed/34698396", "http://www.ncbi.nlm.nih.gov/pubmed/35293986", "http://www.ncbi.nlm.nih.gov/pubmed/28388403", "http://www.ncbi.nlm.nih.gov/pubmed/30355688"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35293986", "text": "death. Necroptosis is a form of regulated cell death, where cells show necrotic morphology. Necroptosis is triggered by death receptors, toll-like rec", "offsetInBeginSection": 663, "offsetInEndSection": 813, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32156734", "text": "to promote MLKL polymerization. Interestingly, knockdown of Hsp70 in cells leads to MLKL destabilization, suggesting that MLKL might also be a client ", "offsetInBeginSection": 1146, "offsetInEndSection": 1296, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34698396", "text": "quitylation during necroptosis, yet neither the mechanism nor the significance of this event has been demonstrated. Here, we show that necroptosis-spe", "offsetInBeginSection": 324, "offsetInEndSection": 474, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34539677", "text": "oss for species adaptation and suggests that necroptosis is not required for normal mammalian development. Moreover, this study highlights a co-evolut", "offsetInBeginSection": 1534, "offsetInEndSection": 1684, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31138766", "text": " exocytosis. Thus, cells undergoing necroptosis need to overcome these independent suppressive mechanisms before plasma membrane disruption can occur.", "offsetInBeginSection": 664, "offsetInEndSection": 814, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28388403", "text": "m MLKL-mediated disruption of the cell membrane. In this issue of Cell, Gong et\u00a0al. challenge the notion that MLKL activation is a point of no return ", "offsetInBeginSection": 83, "offsetInEndSection": 233, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27158445", "text": "chanisms by which the essential, and possibly terminal, necroptotic effector, MLKL, triggers the disruption of cellular membranes to cause cell lysis.", "offsetInBeginSection": 905, "offsetInEndSection": 1055, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32156734", "text": "neage kinase domain-like protein (MLKL), which mediate proinflammatory cell membrane disruption. We screened compound libraries provided by the Nation", "offsetInBeginSection": 200, "offsetInEndSection": 350, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30355688", "text": "zation and membrane translocation, leading to membrane disruption and a loss of cellular ion homeostasis. It has recently been reported that influenza", "offsetInBeginSection": 443, "offsetInEndSection": 593, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35365636", "text": "ed cell death that arises from disruption of cell membranes by the mixed lineage kinase domain-like (MLKL) pseudokinase after its activation by the up", "offsetInBeginSection": 53, "offsetInEndSection": 203, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414c3f3690f196b51000005", "type": "summary", "body": "What is the definition of dermatillomania?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25307926", "http://www.ncbi.nlm.nih.gov/pubmed/29463978", "http://www.ncbi.nlm.nih.gov/pubmed/33654612", "http://www.ncbi.nlm.nih.gov/pubmed/24091067", "http://www.ncbi.nlm.nih.gov/pubmed/21323095"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24091067", "text": "enticity of which was difficult to confirm. The diagnosis of comorbid factitious disorder with dermatillomania was retained. In view of reducing self-", "offsetInBeginSection": 538, "offsetInEndSection": 688, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33654612", "text": "Skin picking disorder, also termed dermatillomania is a condition that leads to repetitive\u00a0picking of their skin ending up in skin and soft tissue dam", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29463978", "text": "Dermatillomania is a rare disease that seldom affects the genitals. Genital dermatillomania has not yet been recognized as a separate entity within th", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21323095", "text": "Dermatillomania is a pathologic grooming disorder characterized by repetitive, ritualistic, impulsive skin picking without an underlying dermatologic ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25307926", "text": "Dermatillomania is a disorder in which a person habitually picks their skin, and this is a form of self-injury. It can involve any part of the body, b", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eeeb70f36125a426000005", "type": "factoid", "body": "What disease can be treated with Glofitamab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34263696", "http://www.ncbi.nlm.nih.gov/pubmed/35626120", "http://www.ncbi.nlm.nih.gov/pubmed/33739857", "http://www.ncbi.nlm.nih.gov/pubmed/36078155", "http://www.ncbi.nlm.nih.gov/pubmed/34953862", "http://www.ncbi.nlm.nih.gov/pubmed/34941996"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34953862", "text": "ch for selection of FIH starting dose for a CD20xCD3 bispecific antibody in B-cell lymphoma, evidenced in the glofitamab study, NP30179 (NCT03075696).", "offsetInBeginSection": 1206, "offsetInEndSection": 1356, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34263696", "text": " welcome addition to the treatment possibilities for patients with B-cell lymphomas who otherwise have limited therapeutic options. The current data a", "offsetInBeginSection": 809, "offsetInEndSection": 959, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36078155", "text": "these patients are lacking. We report two cases of patients with mantle cell lymphoma who relapsed after CAR T therapy and were treated with the bispe", "offsetInBeginSection": 602, "offsetInEndSection": 752, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35626120", "text": "at glofitamab treatment is well tolerated and effective in patients with DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR T-cell ", "offsetInBeginSection": 1125, "offsetInEndSection": 1275, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34941996", "text": "30179, a first-in-human, phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma. Preclinical studies showed that glofitamab leads to T-cell ", "offsetInBeginSection": 110, "offsetInEndSection": 260, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33739857", "text": " I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Data for single-agent glofitamab, with obinutuzumab", "offsetInBeginSection": 174, "offsetInEndSection": 324, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33739857", "text": "tion.\n\n\nCONCLUSION\nIn patients with predominantly refractory, aggressive B-NHL, glofitamab showed favorable activity with frequent and durable CRs and", "offsetInBeginSection": 1742, "offsetInEndSection": 1892, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33739857", "text": "se of glofitamab. This trial included heavily pretreated patients with R/R B-NHL; most were refractory to prior therapy (155; 90.6%) and had received ", "offsetInBeginSection": 839, "offsetInEndSection": 989, "beginSection": ["abstract"], "endSection": "abstract"}]}]}